<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">104441</article-id><article-id pub-id-type="doi">10.7554/eLife.104441</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.104441.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Giménez-Orenga</surname><given-names>Karen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9790-7327</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Martín-Martínez</surname><given-names>Eva</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3261-494X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Nathanson</surname><given-names>Lubov</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1038-9083</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Oltra</surname><given-names>Elisa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0598-2907</contrib-id><email>elisa.oltra@ucv.es</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03d7a9c68</institution-id><institution>Escuela de Doctorado, Catholic University of Valencia</institution></institution-wrap><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0396mnx76</institution-id><institution>National Health Service, Manises Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042bbge36</institution-id><institution>Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University</institution></institution-wrap><addr-line><named-content content-type="city">Fort Lauderdale</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03d7a9c68</institution-id><institution>Department of Pathology, School of Health Sciences, Catholic University of Valencia</institution></institution-wrap><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dopkins</surname><given-names>Nicholas</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bxt4m23</institution-id><institution>Northwell Health</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>05</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP104441</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-12-10"><day>10</day><month>12</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.05.561025"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-05"><day>05</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104441.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-15"><day>15</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.104441.2"/></event></pub-history><permissions><copyright-statement>© 2025, Giménez-Orenga et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Giménez-Orenga et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-104441-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-104441-figures-v1.pdf"/><abstract><p>Research of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM), two acquired chronic illnesses affecting mainly females, has failed to ascertain their frequent co-appearance and etiology. Despite prior detection of human endogenous retrovirus (HERV) activation in these diseases, the potential biomarker value of HERV expression profiles for their diagnosis, and the relationship of HERV expression profiles with patient immune systems and symptoms had remained unexplored. By using HERV-V3 high-density microarrays (including over 350k HERV elements and more than 1500 immune-related genes) to interrogate the transcriptomes of peripheral blood mononuclear cells from female patients diagnosed with ME/CFS, FM, or both, and matched healthy controls (<italic>n</italic> = 43), this study fills this gap of knowledge. Hierarchical clustering of HERV expression profiles strikingly allowed perfect participant assignment into four distinct groups: ME/CFS, FM, co-diagnosed, or healthy, pointing at a potent biomarker value of HERV expression profiles to differentiate between these hard-to-diagnose chronic syndromes. Differentially expressed HERV–immune–gene modules revealed unique profiles for each of the four study groups and highlighting decreased γδ T cells, and increased plasma and resting CD4 memory T cells, correlating with patient symptom severity in ME/CFS. Moreover, activation of HERV sequences coincided with enrichment of binding sequences targeted by transcription factors which recruit SETDB1 and TRIM28, two known epigenetic silencers of HERV, in ME/CFS, offering a mechanistic explanation for the findings. Unexpectedly, HERV expression profiles appeared minimally affected in co-diagnosed patients denoting a new nosological entity with low epigenetic impact, a seemingly relevant aspect for the diagnosis and treatment of this prevalent group of patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HERV</kwd><kwd>ME/CFS</kwd><kwd>fibromyalgia</kwd><kwd>epigenetics</kwd><kwd>immunology</kwd><kwd>biomarker</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001981</institution-id><institution>ME Research UK</institution></institution-wrap></funding-source><award-id>SC036942</award-id><principal-award-recipient><name><surname>Oltra</surname><given-names>Elisa</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003359</institution-id><institution>Generalitat Valenciana</institution></institution-wrap></funding-source><award-id>CIAICO/2021/103</award-id><principal-award-recipient><name><surname>Oltra</surname><given-names>Elisa</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003359</institution-id><institution>Generalitat Valenciana</institution></institution-wrap></funding-source><award-id>ACIF2021/179</award-id><principal-award-recipient><name><surname>Giménez-Orenga</surname><given-names>Karen</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Transcriptomic profiling of HERV elements at the loci level differentiates ME/CFS, fibromyalgia, and their overlap, revealing distinct immuno-epigenetic landscapes.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), classified by the WHO with the ICD-11 8E49 code as a postviral fatigue syndrome, and fibromyalgia (FM) (ICD-11 MG30.0 for chronic primary pain) (<xref ref-type="bibr" rid="bib32">Harrison et al., 2021</xref>), are chronic, disabling, acquired diseases, characterized by complex symptomatology that affects multiple organs (<xref ref-type="bibr" rid="bib2">Bateman et al., 2021</xref>; <xref ref-type="bibr" rid="bib82">Wolfe et al., 2010</xref>). Diagnosis of ME/CFS and FM continues to be based on the clinical assessment of unspecific symptoms, such as debilitating fatigue, generalized pain, cognitive impairment or intestinal, sleep, and immune disturbances (<xref ref-type="bibr" rid="bib12">Carruthers et al., 2011</xref>; <xref ref-type="bibr" rid="bib11">Carruthers et al., 2003</xref>; <xref ref-type="bibr" rid="bib83">Wolfe et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Wolfe et al., 2010</xref>; <xref ref-type="bibr" rid="bib81">Wolfe et al., 1990</xref>). Their frequent co-diagnosis drove the hypothesis of a single syndrome and promoted the search for common or differentiating factors (<xref ref-type="bibr" rid="bib1">Abbi and Natelson, 2013</xref>; <xref ref-type="bibr" rid="bib60">Natelson, 2019</xref>; <xref ref-type="bibr" rid="bib79">Wessely et al., 1999</xref>). However, despite molecular support for ME/CFS and FM constituting different entities (<xref ref-type="bibr" rid="bib29">Groven et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Light et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Nepotchatykh et al., 2023</xref>), their frequent joint appearance (over 50% in females) (<xref ref-type="bibr" rid="bib14">Castro-Marrero et al., 2017</xref>) remains enigmatic.</p><p>Extensive research into ME/CFS and FM has not yet been able to ascertain their origin and pathophysiology. However, several environmental factors have been suggested as triggering agents (<xref ref-type="bibr" rid="bib16">Chu et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Furness et al., 2018</xref>; <xref ref-type="bibr" rid="bib77">Tschopp et al., 2023</xref>). Viral infections are, particularly, gaining momentum after the emergence of a type of persistent post-viral syndrome with symptoms that closely resemble those in ME/CFS (<xref ref-type="bibr" rid="bib42">Komaroff and Lipkin, 2023</xref>) and FM (<xref ref-type="bibr" rid="bib17">Clauw and Calabrese, 2024</xref>), which has been defined as post-COVID-19 condition (ICD-11 RA02) (<xref ref-type="bibr" rid="bib75">Soriano et al., 2022</xref>). The prevalence of post-COVID-19 cases meeting ME/CFS criteria has been estimated at 58% (<xref ref-type="bibr" rid="bib36">Jason and Dorri, 2022</xref>) raising concerns of a health, social, and economic burden of unprecedented dimensions.</p><p>Viral infections trigger dramatic changes in host cells gene expression, affecting their metabolism and epigenetic landscape (<xref ref-type="bibr" rid="bib51">Liu et al., 2020</xref>). Although functionally not well understood, these epigenetic changes involve de-repression of human endogenous retroviruses (HERVs) (<xref ref-type="bibr" rid="bib52">Macchietto et al., 2020</xref>) sequences that were incorporated from exogenous viral infections during evolution and that currently represent about 8% of our genome (<xref ref-type="bibr" rid="bib26">Giménez-Orenga and Oltra, 2021</xref>). In fact, SARS-CoV-2 infection alters peripheral blood mononuclear cell (PBMC) ERV expression in human, monkey, and mice expressing human ACE2 receptors, associating with immune-response activation and histone modification genes in severe COVID-19 cases (<xref ref-type="bibr" rid="bib31">Guo et al., 2024</xref>), and the presence of HERV proteins in postmortem tissues of lungs, heart, gastrointestinal tract, brain olfactory bulb, and nasal mucosa from COVID-19 patients (<xref ref-type="bibr" rid="bib15">Charvet et al., 2023</xref>).</p><p>Although still poorly understood, advances in sequencing technology have aided in the discovery of the wide range of physiological processes in which HERV participate, including coordination of the immune response (<xref ref-type="bibr" rid="bib38">Kassiotis, 2023</xref>), interaction with microbiota (<xref ref-type="bibr" rid="bib20">Dopkins et al., 2022</xref>; <xref ref-type="bibr" rid="bib50">Lima-Junior et al., 2021</xref>), or shaping neurological functions (<xref ref-type="bibr" rid="bib23">Ferrari et al., 2021</xref>), among other. Derangement of HERV expression associates with disease (e.g., multiple sclerosis; <xref ref-type="bibr" rid="bib30">Gruchot et al., 2023</xref>), systemic lupus erythematosus (<xref ref-type="bibr" rid="bib39">Khadjinova et al., 2022</xref>), or post-COVID-19 condition (<xref ref-type="bibr" rid="bib27">Giménez-Orenga et al., 2022</xref>). Particularly, the expression of HERV-encoded proteins has been shown to stimulate an immune response present in autoimmunity (<xref ref-type="bibr" rid="bib30">Gruchot et al., 2023</xref>; <xref ref-type="bibr" rid="bib39">Khadjinova et al., 2022</xref>). In addition, HERV influence on pathophysiology extends to their long terminal repeats (LTRs) regulatory regions, shaping host gene expression (<xref ref-type="bibr" rid="bib35">Ito et al., 2017</xref>).</p><p>Previous studies detected overexpression of some HERV families in immune cells of ME/CFS (<xref ref-type="bibr" rid="bib70">Rodrigues et al., 2019</xref>) and FM (<xref ref-type="bibr" rid="bib64">Ovejero et al., 2020</xref>) at the transcript level. However, the use of directional RT-qPCR (reverse transcription followed by quantitative polymerase chain reaction)-based approaches using degenerated primers limited the detection of affected genomic loci. In this study, we elevated these analyses to obtain genome-wide HERV profiles (HERV expression profiles) of patients having received ME/CFS, FM diagnosis, or both, hypothesizing that HERV expression profiles may reveal distinct underlying pathomechanisms that justify their classification as separate diseases, and/or common fingerprints explaining their joint high prevalence. To test our hypothesis, we scrutinized HERV and gene transcriptomes by using high-density microarray technology in a selected cohort of female patients carefully phenotyped by a single expert clinician into three defined groups of patients: patients fulfilling Canadian and International ME/CFS diagnosis criteria (<xref ref-type="bibr" rid="bib12">Carruthers et al., 2011</xref>; <xref ref-type="bibr" rid="bib11">Carruthers et al., 2003</xref>), patients fulfilling FM diagnosis ACR (American College of Rheumatology) criteria (<xref ref-type="bibr" rid="bib83">Wolfe et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Wolfe et al., 2010</xref>; <xref ref-type="bibr" rid="bib81">Wolfe et al., 1990</xref>), or patients complying with both, ME/CFS and FM diagnosis criteria, being called co-diagnosed from now on. The results of comparing HERV profiles within PBMCs across these three patient groups as well as to HERV profiles of matched healthy subjects allowed, not only for the separation of patients from healthy individuals but also for perfect discrimination of patients into three distinct disease groups, suggesting distinct subjacent pathomechanisms. Unexpectedly, HERV expression profiles appeared minimally affected in co-diagnosed patients denoting a new nosological entity with low epigenetic impact. In addition, HERV profiling also exposed some commonalities between the FM and ME/CFS subgroups and marked quantitative differences within the ME/CFS group that correlated with immune disturbances and patient symptomatology, aspects that may well set new criteria for the differential diagnosis of FM and ME/CFS as well as for patient subtyping with expected impact in precision medicine programs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Demographics and clinical characteristics of participants</title><p>The study compared a total of 43 female subjects: 8 ME/CFS cases, 10 FM, 16 co-diagnosed cases, and 9 matched healthy controls (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The average age for participants was 54 ± 3 years (range 50–58) for ME/CFS subjects, 50 ± 5 years (range 42–58) for FM, 47 ± 15 years (range 22–70) for co-diagnosed individuals, and 51 ± 6 (range 43–61) for controls (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>). Questionnaires used for patient symptom phenotyping included Fibromyalgia Impact Questionnaire (FIQ) (<xref ref-type="bibr" rid="bib10">Burckhardt et al., 1991</xref>), Multi Fatigue Inventory (MFI) (<xref ref-type="bibr" rid="bib74">Smets et al., 1995</xref>) for general fatigue, and Short-Form-36 Health Survey (SF-36) (<xref ref-type="bibr" rid="bib58">Mchorney et al., 1993</xref>) for quality-of-life assessment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Average total and subdomain scores are shown in <xref ref-type="table" rid="table1">Table 1</xref> for each patient group, while itemized questionnaire scores are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>. According to total FIQ scores, after considering that a score &lt;39 indicates mild affection, ≥39 through ≤59 is assigned to moderately affected patients, and &gt;59 to severe affection (<xref ref-type="bibr" rid="bib69">Rivera and González, 2004</xref>) around 88% of cases in the studied cohort correspond with severe cases while 12% are moderate. No statistically significant difference between patient groups was observed for any questionnaire domain except for MFI Physical Fatigue (p = 0.011) and Reduced Motivation (p = 0.038), and only between the ME/CFS and co-diagnosed groups (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>DE of HERV elements discriminates myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and co-diagnosis.</title><p>(<bold>A</bold>) Volcano plots showing log<sub>2</sub>(fold changes) and the adjusted p-values for all HERV assessed with HERV-V3 microarray for each set of groups, as indicated. Red dots indicate DE HERV (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1). Gray boxes show numbers of overexpressed or underexpressed HERV elements. (<bold>B</bold>) HERV expression heatmap and cluster analysis of ME/CFS (<italic>n</italic> = 8, green), FM (<italic>n</italic> = 10, orange), co-diagnosed (<italic>n</italic> = 16, yellow), and healthy control (<italic>n</italic> = 9, blue) samples. The heatmap includes all HERV probes displaying significant DE between at least two of the compared groups (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1). Clusters 1–4 correspond to groups of HERV probes displaying significant over/under-expression in at least one group. Box and violin plots summarize the distribution and expression levels of the DE probes in each cluster per study group. The scaled mean expression value (<italic>z</italic>-score) for each HERV probe is plotted. Box plots show the median <italic>z</italic>-score value and the first and third quartiles. (<bold>C</bold>) Box and violin plots for Clusters 1 and 2 differentiating ME/CFS subgroups 1 and 2. (<bold>D</bold>) Principal component analysis of DE HERV. (<bold>E</bold>) Bar plot of top 10 DE HERV with greater influence/contribution to principal component 1 (PC1) or principal component 2 (PC2). Statistical tests: unpaired two-sample Wilcoxon test with Benjamini–Hochberg p-value correction (***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Differences between patients and controls.</title><p>(<bold>A</bold>) Clinical data for participating subjects. Violin plots summarize the distribution for demographic variables (age, BMI, and weight), Fibromyalgia Impact Questionnaire (FIQ) subdomains (Function, Overall, and Symptoms) or total FIQ; for Multi Fatigue Inventory (MFI) subdomains (GF: general fatigue, Pfa: physical fatigue, RA: reduced activity, RM: reduced motivation, and MF: mental fatigue), and for Short-Form-36 Health Survey (SF-36) subdomains (PF: physical functioning, RP: role physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role emotional, and MH: mental health). Variables are ordered alphabetically. (<bold>B</bold>) Validation of DE HERV loci by RT-qPCR. Violin plots summarize the distribution and expression level of ΔΔCt values for each sample in each study group. Statistical tests: unpaired two-sample Wilcoxon test with Benjamini–Hochberg p-value correction (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig1-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Patient health status assessment with FIQ, MFI, and SF-36 (<xref ref-type="bibr" rid="bib10">Burckhardt et al., 1991</xref>; <xref ref-type="bibr" rid="bib58">Mchorney et al., 1993</xref>; <xref ref-type="bibr" rid="bib74">Smets et al., 1995</xref>) questionnaires.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle"/><th align="left" valign="middle">Control (<italic>n</italic> = 9)Mean ± SD [range]</th><th align="left" valign="middle">ME/CFS (<italic>n</italic> = 8)Mean ± SD [range]</th><th align="left" valign="middle">FM (<italic>n</italic> = 10)Mean ± SD [range]</th><th align="left" valign="middle">Co-diagnosed (<italic>n</italic> = 16)Mean ± SD [range]</th></tr></thead><tbody><tr><td align="left" valign="middle">Age</td><td align="left" valign="top">51 ± 2 [43–61]</td><td align="left" valign="middle">54 ± 3 [50–58]</td><td align="left" valign="middle">50 ± 5 [42–58]</td><td align="left" valign="middle">47 ± 15.48 [22 – 58]</td></tr><tr><td align="left" valign="middle">BMI</td><td align="left" valign="top">25.03 ± 2.07 [22.10–28.04]</td><td align="left" valign="middle">26.29 ± 3.33 [21.34–31.22]</td><td align="left" valign="middle">25.31 ± 1.73 [23.68–28.40]</td><td align="left" valign="middle">24.80 ± 4.72 [18.71–30.43]</td></tr><tr><td align="left" valign="middle">FIQ</td><td align="left" valign="top"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">Total FIQ</td><td align="left" valign="top">28.16 ± 13.08 [0–2.86]</td><td align="left" valign="middle">74.4 ± 4.8 [56.3–85.6]</td><td align="left" valign="middle">75.9 ± 3.4 [51.6–92.8]</td><td align="left" valign="middle">74.6 ± 2.5 [47.8–96.3]</td></tr><tr><td align="left" valign="middle">Function</td><td align="left" valign="top">2.38 ± 0.57 [1.98–3.63]</td><td align="left" valign="middle">5.2 ± 2.2 [1.7–7.9]</td><td align="left" valign="middle">6.8 ± 1.5 [4.3–8.9]</td><td align="left" valign="middle">5.2 ± 1.8 [1.7–9.2]</td></tr><tr><td align="left" valign="middle">Overall</td><td align="left" valign="top">10.01 ± 0 [10.01–10.01]</td><td align="left" valign="middle">8.9 ± 3.0 [1.4–10.0]</td><td align="left" valign="middle">8.2 ± 3.4 [0–10.0]</td><td align="left" valign="middle">7.9 ± 2.7 [1.4–10]</td></tr><tr><td align="left" valign="middle">Symptoms</td><td align="left" valign="top">0.32 ± 0.95 [0–2.86]</td><td align="left" valign="middle">6.6 ± 4.8 [0–10.0]</td><td align="left" valign="middle">6.0 ± 3.4 [0–10.0]</td><td align="left" valign="middle">6.2 ± 2.5 [2.9–10]</td></tr><tr><td align="left" valign="middle">MFI</td><td align="left" valign="top"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">General fatigue</td><td align="left" valign="top">11.56 ± 4.19 [5–17]</td><td align="left" valign="middle">17.6 ± 3.1 [11–20]</td><td align="left" valign="middle">16.3 ± 4.6 [10–20]</td><td align="left" valign="middle">13.6 ± 3.2 [7–20]</td></tr><tr><td align="left" valign="middle">Physical fatigue</td><td align="left" valign="top">10.11 ± 4.01 [6–17]</td><td align="left" valign="middle">18.0 ± 1.9 [16–20]</td><td align="left" valign="middle">17.0 ± 3.7 [12–20]</td><td align="left" valign="middle">14.1 ± 2.9 [12–20]</td></tr><tr><td align="left" valign="middle">Reduced activity</td><td align="left" valign="top">7.33 ± 2.74 [4–12]</td><td align="left" valign="middle">15.9 ± 3.4 [12–20]</td><td align="left" valign="middle">15.9 ± 4.4 [9–20]</td><td align="left" valign="middle">12.9 ± 2.8 [11–20]</td></tr><tr><td align="left" valign="middle">Reduced motivation</td><td align="left" valign="top">7.22 ± 3.31 [4–15]</td><td align="left" valign="middle">15.4 ± 3.7 [9–19]</td><td align="left" valign="middle">14.8 ± 4.1 [9–20]</td><td align="left" valign="middle">11.6 ± 2.4 [8–16]</td></tr><tr><td align="left" valign="middle">Mental fatigue</td><td align="left" valign="top">7.11 ± 2.93 [4–13]</td><td align="left" valign="middle">15.5 ± 3.7 [11–20]</td><td align="left" valign="middle">15.1 ± 3.8</td><td align="left" valign="middle">13.3 ± 3.1 [9–19]</td></tr><tr><td align="left" valign="middle">SF-36</td><td align="left" valign="top"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">Physical functioning</td><td align="left" valign="top">86.67 ± 13.23 [65–100]</td><td align="left" valign="middle">44.5 ± 14.5 [15–60]</td><td align="left" valign="middle">31.5 ± 13.9</td><td align="left" valign="middle">35.3 ± 14.8 [0–65]</td></tr><tr><td align="left" valign="middle">Role physical</td><td align="left" valign="top">83.33 ± 17.95 [50–100]</td><td align="left" valign="middle">3.2 ± 8.8 [0–25]</td><td align="left" valign="middle">10.6 ± 17.7 [0–43.8]</td><td align="left" valign="middle">14.5 ± 21.9 [0–75]</td></tr><tr><td align="left" valign="middle">Bodily pain</td><td align="left" valign="top">58.61 ± 12.63 [45–80]</td><td align="left" valign="middle">19.3 ± 11.7 [0–32.5]</td><td align="left" valign="middle">19.3 ± 17.8 [0–45]</td><td align="left" valign="middle">17.3 ± 14.2 [0–45]</td></tr><tr><td align="left" valign="middle">General health</td><td align="left" valign="top">65.56 ± 15.09 [35–85]</td><td align="left" valign="middle">18.9 ± 11.0 [3.8–35.0]</td><td align="left" valign="middle">24.8 ± 16.1 [0–50]</td><td align="left" valign="middle">23.4 ± 14.8 [0–45]</td></tr><tr><td align="left" valign="middle">Vitality</td><td align="left" valign="top">56.94 ± 9.08 [43.75–75.00]</td><td align="left" valign="middle">13.6 ± 10.1 [0–30]</td><td align="left" valign="middle">11.1 ± 16.8 [0–43.8]</td><td align="left" valign="middle">14.5 ± 11.6 [0–40]</td></tr><tr><td align="left" valign="middle">Social functioning</td><td align="left" valign="top">84.72 ± 13.66 [62.50–100]</td><td align="left" valign="middle">33.6 ± 21.9 [4.0–77.5]</td><td align="left" valign="middle">25.0 ± 23.2 [0–62.1]</td><td align="left" valign="middle">29.5 ± 25.6 [0–75]</td></tr><tr><td align="left" valign="middle">Role emotional</td><td align="left" valign="top">79.63 ± 20.88 [50–100]</td><td align="left" valign="middle">12.8 ± 35.3 [0–100]</td><td align="left" valign="middle">43.3 ± 37.2 [0–100]</td><td align="left" valign="middle">12.8 ± 38.9 [0–100]</td></tr><tr><td align="left" valign="middle">Mental health</td><td align="left" valign="top">71.67 ± 18.54 [40–95]</td><td align="left" valign="middle">34.9 ± 21.2 [3.4–72.0]</td><td align="left" valign="middle">44.7 ± 19.9 [12–70]</td><td align="left" valign="middle">45.2 ± 17.1 [15–80]</td></tr></tbody></table><table-wrap-foot><fn><p>FIQ, Fibromyalgia Impact Questionnaire; MFI, Multi Fatigue Inventory; SF-36, Short-Form 36 Health Survey; SD, standard deviation; SE, standard error. Range refers to the possible values in the studied group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>HERV signatures discriminate ME/CFS, FM, and co-diagnosed groups from healthy controls</title><p>Genome-wide HERV expression profiles for each of the four study groups (three disease groups: ME/CFS, FM, and co-diagnosed, plus one control group corresponding to healthy participants), using custom high-density Affymetrix HERV-V3 microarrays (<xref ref-type="bibr" rid="bib3">Becker et al., 2017</xref>), showed that a set of 489 HERV (502 probesets) is differentially expressed (DE) between at least two of the groups (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1) (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1C</xref>), confirming dysregulation of particular sets of HERV elements in the immune systems of ME/CFS, FM, and co-diagnosed cases as compared to healthy controls. Volcano plots show the number of HERV elements found significantly over- or under-expressed for each of the comparisons, evidencing an enhanced dysregulation of HERV in ME/CFS as compared to FM, co-diagnosed, or healthy control groups (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Consistently, hierarchical clustering of samples based on DE HERV fingerprints clearly differentiate these pathologies from healthy subjects, strikingly segregating ME/CFS from all other compared groups (<xref ref-type="fig" rid="fig1">Figure 1B</xref>); while hierarchical clustering of DE HERV sequences revealed four main clusters consisting of loci specifically overexpressed (Cluster 1, 251 HERV, 293 probesets) or underexpressed (Cluster 2, 119 HERV, 163 probesets) in ME/CFS, loci specifically overexpressed in FM (Cluster 3, 68 HERV, 74 probesets), and loci underexpressed in all three pathologies (Cluster 4, 54 HERV, 64 probesets). DE of the HERV loci for each study group was corroborated by analysis of HERV expression levels encompassed in each cluster, as illustrated with violin plots (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), with some of the changes being validated by the alternative RT-qPCR approach, as shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</p><p>Closer examination of Clusters 1 and 2 indicated that the ME/CFS group could be subdivided into two subgroups showing differential levels of HERV expression profiles (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). While both ME/CFS subgroups (subgroups 1 and 2) show clear upregulation (Cluster 1, p &lt; 0.0001) or downregulation (Cluster 2, p &lt; 0.0001) of several HERV loci as compared to all the other study groups, they show quantitative differences, with the ME/CFS subgroup 2 exhibiting a more pronounced dysregulation than subgroup 1, particularly affecting the downregulated Cluster 2 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Interestingly, subgroup 2 ME/CFS patients present more accused levels of fatigue (p &lt; 0.05) and reduced motivation as compared to the co-diagnosed group and the ME/CFS subgroup 1 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1D</xref>) indicating that quantitative HERV fingerprint differences might help to assess the degree of ME/CFS severity.</p><p>In line with our findings, unsupervised principal component analysis (PCA) of DE HERV loci supports perfect discrimination of samples by study group and differentiates the two identified ME/CFS subgroups (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). While principal component 1 (PC1) perfectly segregates the two ME/CFS subgroups from FM, co-diagnosed, and control groups; principal component 2 (PC2) allows partition of FM, co-diagnosed, and control samples, but not so much of ME/CFS from co-diagnosed cases. Thus, PC1 explains better the variance observed across groups (29.1%) than PC2 (9.3%), suggesting a prominent role of DE HERV loci in ME/CFS pathology. Top 10 contributing HERVs to principal components PC1 and PC2 are shown (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In summary, these results show that ME/CFS, FM, and their co-diagnosis present unique HERV expression profiles capable of discriminating patient subtypes from healthy subjects, providing potential biomarkers for their differential diagnosis and stratification. ME/CFS shows the greatest HERV dysregulation which, importantly, associates with patient symptomatology, suggesting a prominent role of DE HERV in the pathomechanism of this disease, while the co-diagnosed group presents the closest HERV expression profiles to those of healthy controls indicating much less involvement of epigenetic changes in these patients, thus, defining a different nosological entity from ME/CFS or FM.</p></sec><sec id="s2-3"><title>Dysregulated HERV families are disease specific</title><p>Since preferential HERV-family derangements may indicate particularly altered functions in disease (<xref ref-type="bibr" rid="bib35">Ito et al., 2017</xref>), we next examined the family composition of the identified DE HERV clusters (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Overall, ME/CFS (Clusters 1 and 2) outstands with the largest heterogeneity with up to 66 HERV dysregulated families, contrasting with only 22 families in FM (Cluster 3) and 16 in Cluster 4, the latter representing DE HERV common to all patient groups (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Diverse solitary long terminal repeat (LTR) families are deregulated in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and co-diagnosed conditions.</title><p>(<bold>A</bold>) Relative contribution of HERV families to each cluster, calculated as the proportion of HERV loci assigned to each family relative to total HERV loci in each cluster. Families with a representation of at least 2.5% are shown. Main HERV families (<bold>B</bold>) downregulated in ME/CFS, FM and co-diagnosed groups (Cluster 4), (<bold>C</bold>) upregulated in ME/CFS (Cluster 1), (<bold>D</bold>) downregulated in ME/CFS (Cluster 2), and (<bold>E</bold>) upregulated in FM (Cluster 3). Box and violin plots summarize distributions and expression levels of the different HERV probes belonging to the same family in the different study groups. The scaled mean expression value (<italic>z</italic>-score) for each HERV probe is plotted. Box plots show the median <italic>z</italic>-score value and the first and third quartiles. (<bold>F</bold>) Proportion of HERV subdomains expressed by cluster. (<bold>G</bold>) Genomic context of the DE HERV loci by cluster. Statistical tests: Fisher’s exact test, <italic>t</italic>-test or Wilcoxon test with Benjamini–Hochberg p-value correction (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>DE HERV families by study group.</title><p>Violin plots summarize the distribution and expression levels of HERV probesets (log<sub>2</sub>(mRNA expression level)) from a specific family for each sample in each study group. Statistical tests: unpaired two-sample Wilcoxon test with Benjamini–Hochberg p-value correction. (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>DE HERV structures by study group.</title><p>Violin plots summarize the distribution and expression levels of HERV probesets (log<sub>2</sub>(mRNA expression level)) from a specific HERV structure for each sample in each study group. Statistical tests: unpaired two-sample Wilcoxon test with Benjamini–Hochberg p-value correction (**p &lt; 0.01, ***p &lt; 0.001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>DE HERV genomic location by study group.</title><p>Violin plots summarize the distribution and expression levels of HERV probesets (log<sub>2</sub>(mRNA expression level)) from a specific HERV structure for each sample in each study group. Statistical tests: unpaired two-sample Wilcoxon test with Benjamini–Hochberg p-value correction (, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Intergenic solo long terminal repeat (LTR) DE across study groups.</title><p>Intergenic solo LTR expression heatmap of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (<italic>n</italic> = 8, green), fibromyalgia (FM) (<italic>n</italic> = 10, orange), co-diagnosed (<italic>n</italic> = 16, yellow), and healthy control (<italic>n</italic> = 9, blue) samples. The heatmap includes all solo LTR probes displaying significant DE between at least two of the compared groups (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig2-figsupp4-v1.tif"/></fig></fig-group><p>Among DE HERV families 8 appear to be common across all clusters, and 6 of them represent the most abundantly deregulated (&gt;2.5%) (MLT1, MST, THE1, HERV16, ERVL, and HERVL33) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>), suggesting an unspecific association with all disease groups. Within these families, however, MLT1 appears as the only significantly downregulated in all patient groups (p &lt; 0.01) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), accounting for more than a third of the DE HERV in each cluster (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>), a finding that may be, at least partially, due to the fact of MLT1 being the most abundant HERV family in the human genome (<xref ref-type="fig" rid="fig2">Figure 2A</xref>).</p><p>Interestingly, unique sets of DE HERV families were found for each disease (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>). Up to 21 families, comprising HERV-H, HUERSP3, and RRHERVI among other, appeared specifically upregulated in Cluster 1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>), while 12 families, including HERV-P, HERV-Rb, and HERV-XA34, were specifically silenced in Cluster 2, both strikingly DE in ME/CFS patients from subgroup 2 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>). Regarding FM, three families consisting of HERV-T, LTR84, and PRIMA41, were found specifically upregulated (Cluster 3) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>). Five families were commonly downregulated across ME/CFS, FM, and co-diagnosed groups, including HERV-W, HERVK14C, and MER67 (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>). Contrary to the literature (<xref ref-type="bibr" rid="bib64">Ovejero et al., 2020</xref>), reporting upregulation of HERV-W family in FM, our results showed downregulation of HERV-W family in all patient groups, more accentuated in FM and co-diagnosed groups than ME/CFS with respect to healthy levels (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). In all, these results reveal family-specific derangement of HERV expression in immune cells of FM and ME/CFS but not in co-diagnosed cases.</p><p>In light of the potential involvement of HERV-encoded proviral proteins in disease development (<xref ref-type="bibr" rid="bib26">Giménez-Orenga and Oltra, 2021</xref>) and to deepen the analysis of disease-specific HERV fingerprints, we then determined the proportion of these HERV fingerprints corresponding to solitary and proviral elements, as well as the different subdomains of the HERV structure according to probe detection in the microarrays that is, LTR containing regulatory sequences versus gag, pol, and env protein-coding genes. Although functional information of these sequences is quite limited, the nature of the detected HERV motifs may inform of potential regulatory mechanisms leading to or perpetuating disease status (e.g., toxic env proteins or non-coding regulatory sequences). In agreement with hg38 HERV genomic data, it was found that the great majority of the dysregulated HERV loci corresponded to solitary LTR elements, which are known to be the most abundant in our genome, with few exceptions corresponding to proviral HERV (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>Lastly, given the potential of HERV LTRs to influence the expression of neighboring genes through the regulatory elements they hold, we examined the genomic context of the DE HERV loci by cluster (<xref ref-type="fig" rid="fig2">Figure 2G</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Although not allocating significant association to promoter regions, repressed loci in ME/CFS (Cluster 2) and overexpressed loci in FM (Cluster 3) were significantly associated with gene 3′ endings, and silenced loci in the three pathologies (Cluster 4) significantly associated with intronic regions. These results suggest that the molecular mechanisms by which disease-specific deregulated HERV loci could be participating in the development or maintenance of disease likely involve changes in transcript turnover or availability of alternative splicing events. In addition, DE analysis of intergenic solo LTRs show that they are underexpressed in ME/CFS (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>), pointing at the participation of epigenetic regulatory mechanisms in the disease.</p></sec><sec id="s2-4"><title>HERV fingerprints associate with abnormal immune gene expression</title><p>Since disease-associated HERV derangement could indicate, even mediate, differences in global gene expression, we proceeded to analyze potential associations between disease-associated HERV fingerprints and a set of genes involved in eight pathways (immunity, inflammation, cancer, central nervous system disorders, differentiation, telomere maintenance, chromatin structure, and gag-like genes) detected by probes present in this same HERV-V3 high-density microarrays (<xref ref-type="bibr" rid="bib3">Becker et al., 2017</xref>). Differential transcript analysis revealed 368 genes (1037 probesets) DE between at least two study groups (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1F</xref>). In line with DE HERV expression, ME/CFS immune cells showed a more accused dysregulation in gene expression profiles compared to FM’s and co-diagnosed groups (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Hierarchical clustering of samples and PCA based on DE genes, however, did not cluster all samples by study group as HERV signatures did, with the only exception of ME/CFS subgroup 2, which exhibited a markedly different gene expression profile further supporting its distinction from the remaining study groups (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>HERV expression correlates with immune-response genes.</title><p>Hierarchical clustering of DE HERV and genes (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1) providing eight modules with highly correlated expression levels. Box and violin plots summarize the distribution and expression level of the different HERV (blue) and gene (green) probes in Modules (<bold>A</bold>) 1 and 6, (<bold>B</bold>) 3 and 4, and (<bold>C</bold>) 2, 5, 7, and 8, per study group. The scaled mean expression value (<italic>z</italic>-score) for each HERV and gene probe sets are plotted. Box plots show the median <italic>z</italic>-score values with first and third quartiles. Statistical tests: Wilcoxon test (****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Differential gene expression for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and comorbidity groups.</title><p>(<bold>A</bold>) Volcano plots showing the log<sub>2</sub>(fold change) and the adjusted p-value for all the genes assessed by HERV-V3 microarray in each comparison by condition. Red dots indicate differentially expressed genes (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1). Gray boxes indicate the number of upregulated and downregulated HERVs. (<bold>B</bold>) Gene expression heatmap and principal component analysis (PCA) of ME/CFS (<italic>n</italic> = 8), FM (<italic>n</italic> = 10), comorbidity (<italic>n</italic> = 16), and healthy control (<italic>n</italic> = 9) samples. Sample groups are color-coded in green, orange, yellow, and blue, respectively. The heatmap and PCA include all gene probes displaying significant differential expression between at least two groups (FDR &lt;0.1 and |log<sub>2</sub>FC| &gt;1).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To uncover potentially affected physiologic functions linked to DE HERV, we examined how DE HERVs and DE genes with similar expression patterns grouped together in modules based on their intrinsic relationships by their hierarchical co-clustering (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Then, the functional significance of these modules was assessed by gene ontology (GO) analysis of the DE genes within each module. The hierarchical clustering analysis resulted in the identification of eight distinct modules, each characterized by unique combinations of DE HERV and DE gene patterns across all four study groups (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In particular, 37 HERV (19 from Module 1 and 18 from Module 6) with decreased expression levels across the three disease groups, correlated with several genes involved in the differentiation of immune cells and regulation of cell–cell adhesion (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Remarkably, ME/CFS exhibited upregulation of 258 HERV loci with expression levels that correlated with 34 genes involved in alpha-beta T cell activation and T-helper 17 cell commitment-related genes (Module 3). In addition, 78 HERV downregulated in ME/CFS correlated with pathogen detection-related genes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, GO:0016045, GO:0016032, GO:0098543), suggesting a special involvement of the immune system in the disease. Lastly, several HERV and genes exhibited upregulated expression in FM while appearing downregulated in ME/CFS. These FM-specific DE expressed genes are involved in telomere structure organization and maintenance (Modules 2 and 5), cellular response to glucocorticoids (Module 7), and regulation of NF-κB signaling (Module 8) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), indicating divergent immune states in ME/CFS and FM with a differential impact in inflammatory processes.</p></sec><sec id="s2-5"><title>Co-expression of DE HERV and immune-response genes predominantly occur by mechanisms other than co-transcription</title><p>To further investigate the relationship between HERV dysregulation and immune abnormalities, we mapped the genomic localization of HERV and genes within each module, looking for genomic overlaps that could explain their correlation by co-expression. Surprisingly, the results showed no major overlaps of DE HERV and their correlated DE genes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), with distances that separate them at least 100 kbp (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1G</xref>), thereby suggesting overall independent expression of DE HERV and DE genes. As an exception, it was noticed that some elements from the MLT1 family co-localized with DE genes within a 30 kbp window (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1G</xref>). For example, the element MLT1_5q32, from Module 1, appears located 18,114 bp upstream of the <italic>CD74</italic> gene, involved in MHC class II antigen processing, or the element MLT1_4q24, belonging to Module 6, lies within <italic>NFκB1</italic> first intron. Both HERV loci and their co-localized genes exhibited downregulation in ME/CFS, FM, and co-diagnosed groups (p &lt; 0.05). Likewise, an exception was noticed for the MLT1_8q12.1 and MLT1_Xp22.3 HERV elements in Module 2, located within <italic>LYN</italic>’s tenth intron and <italic>TLR8</italic>-long isoform’s second exon, respectively. Their genomic co-localization may explain that their specific lower expression levels in the ME/CFS subgroup 2 occur as result of co-transcription (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>DE HERV sequences and DE immune-response genes are majorly independently transcribed.</title><p>(<bold>A</bold>) Genomic distribution of HERV, and genes encompassed in Modules 1 through 8. (<bold>B</bold>) Genomic distance between DE HERV and their nearest DE genes per module, plotted as density curves illustrating the distribution of distances from 0 to 100 million base pair (Mbp). (<bold>C</bold>) Violin dot plots showing the distribution and expression levels of some examples of co-localized HERV loci and genes in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subgroup 1 (<italic>n</italic> = 3), ME/CFS subgroup 2 (<italic>n</italic> = 5), FM (<italic>n</italic> = 10), co-diagnosed (<italic>n</italic> = 16), and healthy control (<italic>n</italic> = 9) samples. Blue and orange highlighted headings indicates the pair HERV/gene belonged to Modules 1 or 6, or Modules 2, 5, 7, or 8, respectively. (<bold>D</bold>) Heatmap of enriched transcription factor binding sites (TFBS) in HERV loci of Modules 1 through 7. Module 8 did not show significant enrichment of TFBS. Statistical tests: Wilcoxon test (*p &lt; 0.05; **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Gene ontology analysis of transcription factors binding sites enriched in HERV loci of Modules 1–7.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Since common <italic>trans</italic>-regulatory mechanisms may explain correlation by co-expression in the absence of co-transcription, we analyzed DE HERV in each module for potential enrichment in transcription factor binding sites (TFBS) by comparing the annotated TFBS within dysregulated HERV genomic regions against the full set of TFBS in the genome (based on publicly available human ChIP-seq data provided by ReMap2022) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Then, we performed GO analysis for HERV-gene sets enriched TFBS to infer their function (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Interestingly enough, the results showed enrichment of binding sites for transcription factors involved in the immune response in Modules 1 through 7, further supporting the role of immune disturbances in ME/CFS, FM, and co-diagnosed cases, while no significant enrichment of TFBS was found in Module 8. In addition, HERV downregulated across the three patient groups (Modules 1 and 6) were enriched in TFBS involved in angiogenesis, while those upregulated in FM but downregulated in ME/CFS (Modules 2, 5, and 7), were enriched in TFBS for miRNA transcription and glucocorticoid signaling. It is worth mentioning that HERV upregulated in ME/CFS (Module 3) were markedly enriched with binding sites for chromatin remodeling factors, from which SETDB1 and TRIM28 stand out as key epigenetic repressors of HERV expression and CTCF for its importance in the establishment of topologically associating domains in chromosomes. These results therefore support the possibility that DE HERV expression occurs independently, but in coordination with their correlated DE genes by yet to define mechanisms, likely driven by and/or driving epigenetic changes in immune cells of ME/CFS patients.</p></sec><sec id="s2-6"><title>DE HERV strongly associates with plasma and T-cell levels</title><p>Given the detected relationships between HERV dysregulation and immunological disturbances, we investigated differences in immune cell populations across the study groups by performing CIBERSORTx analysis on normalized microarray gene expression data. CIBERSORTx is an analytical tool that provides an estimation of cell type abundance using gene expression data (<xref ref-type="bibr" rid="bib63">Newman et al., 2019</xref>). The results point at a decrease in γδ T cells as well as an increase in resting CD4 T memory and plasma cells (p &lt; 0.05) in ME/CFS patients from subgroup 2 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). To further understand the relationship between gene signatures and the potential differences in immune cell populations with DE HERV, we analyzed correlations across HERV and genes included in Modules 1 through 8 and immune cell proportions, finding that dysregulated HERV loci moderately to strongly correlate with plasma cell and resting CD4 memory T cells increase, and γδ T cell population decrease (|<italic>R</italic>| &gt; 0.4, p &lt; 0.01) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Curiously, HERV and genes upregulated in ME/CFS subgroup 2 (Module 3), negatively correlate with γδ T cell abundance (e.g., LTR65_20p11.21, <italic>R</italic> = 0.57, p = 6.3e−05) and positively correlate with resting CD4 memory T cells, and plasma cell abundances (e.g., LTR65_20p11.21, <italic>R</italic> = 0.57, p = 6.3e−05; MER49_11q13.1, <italic>R</italic> = −0.67, p = 1e−06) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), while the tendency of correlation appears reversed for the other modules. These results suggest a potential relationship between HERV expression and immune cell fractions in a subgroup of ME/CFS patients.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>HERV fingerprints correlate with immune cell profiles.</title><p>(<bold>A</bold>) Measurements of immune cell proportions by CIBERSORTx per study group (<italic>n</italic> = 8 myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], <italic>n</italic> = 10 fibromyalgia [FM], <italic>n</italic> = 16 co-diagnosed, <italic>n</italic> = 9 controls). (<bold>B</bold>) Association between modules and immune cell proportions was evaluated by correlating eigengenes from each module with cell proportion values obtained from CIBERSORTx analysis. Boxes show Pearson correlation values and associated p-values (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p&lt;0.0001) between gene expression levels of each module and quantity of cells from each specific type. A value of 1 (green) and –1 (blue) quantify strongest positive and negative correlations, respectively, while 0 (white) shows no correlation. (<bold>C</bold>) Scatter plots between top HERV loci expression levels and immune cell proportion as measured by CIBERSORTx. Pearson correlation coefficients and associated p-values are shown in plots. Correlation 95% confidence intervals are: 0.33–0.74 for LTR65_20p11.21 versus γδ T cells, –0.81 to –0.46 for MER49_11q13.1 versus resting CD4 memory T cells, and –0.70 to –0.25 for MER72_4q34.3 versus plasma cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig5-v1.tif"/></fig></sec><sec id="s2-7"><title>HERV and immune alterations associate with ME/CFS diagnosis</title><p>Lastly, in an effort to detect potential relationships between deregulated HERV and genes, and patient diagnosis, we analyzed the association between DE of HERV and genes belonging to each module and the diagnosis received. Interestingly, activation of HERV and genes involved in immune response (Module 3) seem to strongly associate with diagnosis of ME/CFS (subgroup 2) (|<italic>R</italic>| &gt; 0.89, p &lt; 0.001) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In fact, top correlated genes and HERV with ME/CFS diagnosis (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), showed the strongest association with disease symptoms (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), particularly with some domains of the MFI and SF-36 questionnaires, including physical and mental fatigue (p &lt; 0.05). These results suggest the participation of these HERV and genes in ME/CFS disease while uncovering their potential as biomarkers.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>HERV and gene deregulation associates with disease symptomatology.</title><p>(<bold>A</bold>) Association between modules and disease determined by correlations of eigengenes from each module with binarized disease traits. Boxes show Pearson correlation values and associated p-values (*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001) by module and each disease trait. A value of 1 (orange) and –1 (blue) quantify strongest positive and negative correlations, respectively, while 0 (white) shows no correlation. (<bold>B</bold>) Barplots showing top 10 HERV loci (upper) and top 10 genes (lower) with highest correlations with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disease. Bar height and color display the strength of each correlation, being high orange bars more correlated than lower blue bars. (<bold>C</bold>) Association between top 10 HERV loci (left) and top 10 genes (right) with disease traits as determined by their correlation with ME/CFS patient symptoms as assessed by questionnaire scores. Boxes show Pearson correlation values and associated p-values (*p &lt; 0.05, **p &lt; 0.01) by DE HERV or DE gene as indicated for Fibromyalgia Impact Questionnaire (FIQ) subdomains (Function, Overall, and Symptoms) or total FIQ; for Multi Fatigue Inventory (MFI) subdomains (GF: general fatigue, Pfa: physical fatigue, RA: reduced activity, RM: reduced motivation, and MF: mental fatigue), and for Short-Form-36 Health Survey (SF-36) subdomains (PF: physical functioning, RP: role physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, RE: role emotional, and MH: mental health).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-104441-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Researchers have strived for decades to elucidate the etiology and pathophysiology of ME/CFS and FM, with disease complexity and patient heterogeneity hindering this task. With no biomarkers available and unclear pathophysiology, ME/CFS and FM are often misdiagnosed, further complicating the identification of effective treatments. In this study, we tried to overcome patient heterogeneity by studying a very finely phenotyped cohort diagnosed by a single expert clinician, representing one of the few studies (<xref ref-type="bibr" rid="bib61">Nepotchatykh et al., 2023</xref>) including samples of patients diagnosed with either ME/CFS, FM, or both (co-diagnosed group) by two different clinical criteria (Canadian (<xref ref-type="bibr" rid="bib11">Carruthers et al., 2003</xref>) and International Consensus (<xref ref-type="bibr" rid="bib12">Carruthers et al., 2011</xref>) criteria, and the 1990 (<xref ref-type="bibr" rid="bib81">Wolfe et al., 1990</xref>) and 2011 (<xref ref-type="bibr" rid="bib83">Wolfe et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Wolfe et al., 2010</xref>) ACR criteria, respectively). Due to previously reported sex-associated differences in these diseases, only female patients were included, limiting the external validity of the results in the male population while minimizing potential sex-associated bias.</p><p>Triggering agents for ME/CFS and FM, such as infections, stress, or trauma (<xref ref-type="bibr" rid="bib16">Chu et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Furness et al., 2018</xref>), seem capable of disrupting the epigenetic mechanisms constraining HERV expression (<xref ref-type="bibr" rid="bib66">Rangel et al., 2022</xref>). Dysregulation of HERV has been proposed to contain more distinctive features than the host transcriptome itself in response to viral infections (<xref ref-type="bibr" rid="bib56">Marston et al., 2021</xref>), and it is becoming detected in additional complex diseases (<xref ref-type="bibr" rid="bib26">Giménez-Orenga and Oltra, 2021</xref>), offering a new perspective to study their physiopathology. In fact, HERV profiling could constitute an indirect approach (surrogate marker) to evidence epigenetic derangements and 3D alterations of the chromatin structure with obvious functional consequences. Previous research revealed aberrant activation of HERV in ME/CFS (<xref ref-type="bibr" rid="bib70">Rodrigues et al., 2019</xref>) and FM (<xref ref-type="bibr" rid="bib64">Ovejero et al., 2020</xref>). However, these two studies consisting of broad amplification of HERV by degenerate primer sets, did not allow for specific HERV loci identification. In this study, we fill this gap of knowledge by genome-wide analyzing annotated HERV sequences in the human genome and their relationship with immune gene expression and patient symptoms. The results show for the first time a comparison of PBMCs HERV expression profiles of ME/CFS, FM, and co-diagnosed patient groups as compared to HERV expression profiles of healthy subjects. Despite the limited number of samples (8 ME/CFS cases, 10 FM, 16 comorbid cases, and 9 matched healthy controls), our results show a specific HERV fingerprint for each disease that allows perfect discrimination into three distinct patient groups and their separation from healthy participants, opening the possibility of HERV expression profile-based diagnostic of these symptom-related, diseases. Methodology that could be extended to the study of other chronic diseases such as post-COVID-19 condition. Particularly interesting will be to determine whether post-COVID-19 cases present different HERV fingerprints that justify commonalities to ME/CFS and/or FM, or if by contrast show an evolution closer to the more prevalent co-diagnosed state. Worth noting are the results obtained in the co-diagnosed group which, unexpectedly, presented a completely different HERV profile to those identified for ME/CFS and for FM while strikingly closer to that of healthy controls. Findings that support a distinct subjacent pathomechanism for the co-diagnosed group of patients and, therefore, the identification of a novel nosologic entity.</p><p>In addition, our study reveals enhanced HERV dysregulation in the ME/CFS group when compared to FM, co-diagnosed cases, or healthy controls and significant quantitative differences within a more severely affected ME/CFS subgroup (subgroup 2) supporting inter-individual HERV expression variability toward patient subtyping, with potential relevance for patient tailored treatments, and potential for HERV expression levels to define degree of severity in ME/CFS. The study also defined a set of DE HERV commonly downregulated in all three patient groups (ME/CFS, FM, and their co-diagnosis, Cluster 4), a deeper study of which may help explain clinical commonalities between these conditions. In fact, the lack of a specific association of Cluster 4 DE HERV with a patient-study group opens the possibility of their derangement in additional complex and chronic diseases.</p><p>Analysis of DE HERV loci at family level within each cluster interestingly showed the involvement of different HERV families in each of the study groups, with ME/CFS outstanding by the largest heterogeneity, including deregulation in families such as HERV-H or HERV-P. Deregulation of HERV-H and HERV-P families has been previously linked to disease (<xref ref-type="bibr" rid="bib4">Bergallo et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Morris et al., 2019</xref>; <xref ref-type="bibr" rid="bib85">Yi et al., 2006</xref>) with potential involvement in immune function performance (<xref ref-type="bibr" rid="bib28">Goodchild et al., 1993</xref>; <xref ref-type="bibr" rid="bib45">Kulski et al., 1999</xref>; <xref ref-type="bibr" rid="bib53">Mager et al., 1999</xref>; <xref ref-type="bibr" rid="bib55">Mangeney et al., 2001</xref>; <xref ref-type="bibr" rid="bib57">Matsuzawa et al., 2021</xref>). Another HERV family consistently linked to disease is the HERV-W (<xref ref-type="bibr" rid="bib19">Dolei et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Giménez-Orenga et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Kremer et al., 2013</xref>), whose upregulation has been reported in FM (<xref ref-type="bibr" rid="bib64">Ovejero et al., 2020</xref>). Contrarily, our results evidenced downregulation of HERV-W family in all patient groups, particularly the HERV-W-LTRSU3_19q13.42_st element. Dissimilar results may be due to the use of different techniques to evaluate family expression (degenerate primers in RT-qPCR vs. probes in microarray), or accuracy in patient diagnosis. Our study further revealed that the majority of downregulated HERV in ME/CFS, FM, and co-diagnosed groups belonged to a sole HERV family, the MLT1. This family was found enriched near DE genes involved in the response to infection (<xref ref-type="bibr" rid="bib7">Bogdan et al., 2020</xref>). MLT1 family members are among the most frequently overlapping with human lncRNAs (<xref ref-type="bibr" rid="bib65">Ramsay et al., 2017</xref>). However, the potential role of MLT1-derived lncRNAs in the diseases studied here remains speculative at this stage.</p><p>In accordance with genomic data (<xref ref-type="bibr" rid="bib46">Lander et al., 2001</xref>), most deregulated HERV loci consisted of solitary LTRs, known for their ability to influence gene expression through their regulatory sequences (<xref ref-type="bibr" rid="bib35">Ito et al., 2017</xref>). For example, a HERV-H solitary LTR located at the <italic>HHLA2</italic> locus serves as its main polyadenylation signal (<xref ref-type="bibr" rid="bib28">Goodchild et al., 1993</xref>; <xref ref-type="bibr" rid="bib53">Mager et al., 1999</xref>), allowing the encoding of the HHLA2 protein, which regulates CD4 and CD8 T cell functions along with antigen-presenting cell proliferation (<xref ref-type="bibr" rid="bib87">Zhao et al., 2013</xref>). Furthermore, it is known that non-allelic homologous recombination events leading to solitary LTRs create inter-individual variation, not only by removing coding potential but also by altering the <italic>cis</italic>-regulatory or transcriptional activity of the affected particular genomic regions (<xref ref-type="bibr" rid="bib67">Rebollo et al., 2012</xref>; <xref ref-type="bibr" rid="bib76">Thomas et al., 2018</xref>) even causing microdeletions (<xref ref-type="bibr" rid="bib34">Hermetz et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Sanchez-Valle et al., 2010</xref>; <xref ref-type="bibr" rid="bib73">Shuvarikov et al., 2013</xref>), which offer possibilities for exploring familial risk factors of these diseases.</p><p>Analysis of differential gene expression in the exact same samples provided additional evidence of HERV-associated immune changes in the ME/CFS group as compared to FM, co-diagnosed, or healthy control groups, further supporting the existence of two ME/CFS subgroups differing, once more, at the quantitative level only.</p><p>Although genomic localization of correlated HERV and genes suggested major mechanisms other than co-transcription, it should be noted that gene probes included in the microarray do not fully picture the complete mRNA transcriptome, and therefore the possibility that other DE genes locate nearer to deregulated HERV cannot be ruled out. Furthermore, long-range interactions between gene promoters and LTR regulatory elements have been described for some HERV families, including MLT1, MER21, MER41, or LTR54 (<xref ref-type="bibr" rid="bib35">Ito et al., 2017</xref>), reported as DE in this study. In this regard, it has been shown that the HERV-H family, upregulated in ME/CFS subgroup 2, can influence gene expression over long genomic distances, for example by creating topologically associated domains (<xref ref-type="bibr" rid="bib86">Zhang et al., 2019</xref>), perhaps explaining at least some of our findings of DE immune genes being co-expressed with DE HERV. Under the hypothesis that independently transcribed DE HERV could be regulated by the same <italic>trans-</italic>acting mechanisms as DE genes, we interestingly found enrichment for TFBS regulating the immune response within DE HERV, suggesting <italic>trans</italic>-mediated coordination of deranged HERV and gene expression. Furthermore, HERV upregulated in ME/CFS were markedly enriched in chromatin remodeling factor binding sites, including SETDB1 and TRIM28, both being key epigenetic repressors of HERV expression, pointing to the impairment of TRIM28/SETDB1 axis as the underlying mechanism of HERV upregulation in ME/CFS. In support of this possibility, influenza A virus, a suspected trigger of ME/CFS (<xref ref-type="bibr" rid="bib54">Magnus et al., 2015</xref>), has been shown to activate HERV expression by impairing the repressor TRIM28/SETDB1 axis (<xref ref-type="bibr" rid="bib72">Schmidt et al., 2019</xref>).</p><p>As the literature endorses changes in immune cell subsets in ME/CFS (<xref ref-type="bibr" rid="bib9">Brenu et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Brenu et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">Curriu et al., 2013</xref>), we aimed to indirectly measure potentially skewed immune cell type ratios in our study groups with the use of CIBERSORTx software (<xref ref-type="bibr" rid="bib63">Newman et al., 2019</xref>). The detected increase in plasma cells and resting CD4 T memory cells in ME/CFS subgroup 2, suggests the presence or the history of previous infections stimulating the immune system in these subjects, coinciding with greater dysregulation in immune-related genes and HERV upregulation and increased severity of symptoms. On another hand, this same subgroup of patients exhibited lower levels of γδ T cells, an event reported to our knowledge in other autoimmune diseases like systemic lupus erythematosus and psoriasis (<xref ref-type="bibr" rid="bib22">Fay et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Wang et al., 2012</xref>). It has been described that γδ T cells mediate the immune response against viral infections like EBV, HHV-6, or CMV (<xref ref-type="bibr" rid="bib88">Zhao et al., 2018</xref>), which together with natural killer cell dysfunction reported in the mentioned autoimmune diseases (<xref ref-type="bibr" rid="bib33">Henriques et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Kim et al., 2019</xref>) but also in ME/CFS (<xref ref-type="bibr" rid="bib21">Eaton-Fitch et al., 2019</xref>), suggests an impaired cytotoxic function rendering patients with lower counts of this cell type, becoming more susceptible to viral reactivation. Interestingly, anomalies in immune cell abundance highly correlated with observed HERV expression patterns, indicating that HERV deregulation may either reflect expression derangement in those cell subpopulations or somehow influence immune cell ratios. The analysis of PBMC, rather than isolated subpopulations, is limited at distinguishing between these non-exclusive possibilities. In addition, we found strong associations between the HERV elements MER31_3p26.1 and HERV16_3p21.31 expression correlating with physical and mental fatigue according to health status assessment instruments MFI (<xref ref-type="bibr" rid="bib74">Smets et al., 1995</xref>) and SF-36 (<xref ref-type="bibr" rid="bib58">Mchorney et al., 1993</xref>), where higher scores indicate a worse or better health status, respectively. In this regard, both HERV elements, belonging to Module 3, that is, upregulated in ME/CFS subgroup 2, positively and negatively correlated with MFI and SF-36 subdomains, respectively, indicating that increased expression of MER31_3p26.1 and HERV16_3p21.31 elements may affect patient health status. Interestingly enough, previous correlations between HERV expression and physical fatigue are reported in the post-viral syndrome post-COVID-19 condition (<xref ref-type="bibr" rid="bib27">Giménez-Orenga et al., 2022</xref>), which shares symptomatology with ME/CFS (<xref ref-type="bibr" rid="bib42">Komaroff and Lipkin, 2023</xref>). Further study of MER31_3p26.1 and HERV16_3p21.31 elements and their potential pathogenic function seem granted.</p><p>Overall, this study not only shows the potential of HERV expression profiles as biomarkers for ME/CFS, FM, and for the definition of ME/CFS and FM co-diagnosis but also exposes their potential involvement in immune anomalies and connection with patient symptoms in these diseases, with etiological potential. Our results reveal family-specific HERV deregulation in ME/CFS and FM immune cells and their association with changes in pathogen-detection genes and immune cell subsets. Recent findings by <xref ref-type="bibr" rid="bib56">Marston et al., 2021</xref> demonstrated specific disruption of HERV families in response to specific viral infection agents. Perhaps a database enabling the comparison of disease HERV expression profiles with those induced by exogenous infections could help reveal the triggering agents behind diseases of suspected viral etiology, such as ME/CFS and FM.</p><p>In summary, this study pioneers the comparison of female ME/CFS, FM, and co-diagnosed HERV expression profiles showing the superior diagnostic potential of HERV fingerprints over immune transcriptomes, with clinical implications, importantly providing an effective tool for the objective differential diagnosis of these hard-to-diagnose co-occurring diseases. Given the limited sample size of our cohort, validation of the findings in extended cohorts is a must. The potential mechanisms point at underlying epigenetic disturbances strikingly derepressing HERV silencing, particularly in ME/CFS. Whether these disturbances primarily affect certain immune subpopulations, estimated decreased for γδ T cells, or increased for plasma and resting CD4 memory T cells, correlating with patient symptom severity in ME/CFS, or reflect the presence of DEHERV profiles in immune cell subpopulations biased in these patient groups is an aspect that awaits further work.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study design</title><p>This cross-sectional observational study was approved by the Public Health Research Ethics Committee DGSP-CSISP of Valencia, núm. 20190301/12, Valencia, Spain. The study included a total of 43 female patients invited to participate from local patient associations who were clinically diagnosed with ME/CFS (<italic>n</italic> = 8), FM (<italic>n</italic> = 10), or both (<italic>n</italic> = 16) (National Biobank Registry Ref 0006024) and 9 healthy control individuals’ population-matched for age and BMI (National Biobank Registry Ref 0006034). Patients were diagnosed by an FM and ME/CFS specialized clinician (Hospital de Manises, Valencia, Spain) using the 1990 (<xref ref-type="bibr" rid="bib81">Wolfe et al., 1990</xref>) and 2011 (<xref ref-type="bibr" rid="bib83">Wolfe et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Wolfe et al., 2010</xref>) American College of Rheumatology (ACR) criteria for FM and the Canadian (<xref ref-type="bibr" rid="bib11">Carruthers et al., 2003</xref>) and International Consensus (<xref ref-type="bibr" rid="bib12">Carruthers et al., 2011</xref>) criteria for ME/CFS diagnosis. Patients with health problems other than FM and ME/CFS were excluded from the study. Individuals with any similar o related pathology, including a medical history of chronic pain and/or fatigue, or serious health complications, were excluded from control group, as well as medicated healthy controls. Written informed consent was obtained from all study participants and patient health status was also evaluated with the use of standardized questionnaires, including the FIQ case report form (<xref ref-type="bibr" rid="bib10">Burckhardt et al., 1991</xref>; <xref ref-type="bibr" rid="bib69">Rivera and González, 2004</xref>), the MFI questionnaire (<xref ref-type="bibr" rid="bib74">Smets et al., 1995</xref>), and the quality-of-life SF-36 instrument (<xref ref-type="bibr" rid="bib58">Mchorney et al., 1993</xref>). Participating patients agreed to withdraw medication at least 12 hr prior to blood draw. Microarray analysis of RNA extracted from PBMCs was performed along with complementary bioinformatic analysis to evaluate differences in HERV profiles among patients with potential application as biomarkers or indicators of the underlying pathomechanisms.</p></sec><sec id="s4-2"><title>Isolation of PBMCs and total RNA extraction</title><p>Up to 10 ml of whole blood were collected via venipuncture after a 12-hr overnight fasting in K2EDTA tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and processed within 2 hr by dilution at 1:1 (vol/vol) ratio in phosphate-buffered saline solution (PBS) with layering on top of 1 volume of Ficoll-Paque Premium (GE Healthcare, Chicago, IL, USA) and separation by density centrifugation at 500 × <italic>g</italic> for 30 min (20°C, brakes off). The PBMC layer was isolated and washed with PBS and resuspended in red blood cell lysis buffer (155 mM NH<sub>4</sub>Cl, 10 mM NaHCO<sub>3</sub>, 0.1 mM EDTA, and pH 7.4), kept on ice for 5 min, and centrifuged (20°C at 500 × <italic>g</italic> for 10 min), to remove contaminating erythrocytes. The washed pellets were adjusted to a final concentration of 10<sup>7</sup> cells/ml in freezing medium (90% FBS, 10% DMSO), aliquoted, and deeply frozen in liquid nitrogen until use. Total RNA was extracted using RNeasy Mini Kit (QIAGEN, MD, USA) according to the manufacturer’s instructions. RNA quality was assessed using Agilent TapeStation 4200 (Agilent). All RNA samples had an RNA integrity number above 7.</p></sec><sec id="s4-3"><title>Transcriptome analysis by microarray</title><p>To minimize batch effects the samples were anonymized (blinded to the operator) and scrambled across groups. HERV transcriptome was scrutinized using custom high-density HERV-V3 microarrays (<xref ref-type="bibr" rid="bib3">Becker et al., 2017</xref>), capable to discriminate 174,852 HERV elements, 179,142 MaLR elements, and putative active 1072 LINE-1 elements at the locus level, in addition to detecting a set of 1559 genes involved in eight potentially relevant cellular pathways (immunity, inflammation, cancer, central nervous system affections, differentiation, telomere maintenance, chromatin structure, and gag-like genes). These custom HERV-V3 arrays also allow to discern the different subdomains within proviral sequences: 3′ or 5′ LTRs and <italic>gag/pol/env</italic> regions of proviral HERV and solitary LTRs originated after non-allelic recombination events between the two LTRs causing complete proviral elimination (<xref ref-type="bibr" rid="bib76">Thomas et al., 2018</xref>). To analyze HERV transcriptomes of PBMC-derived RNA samples, cDNA was synthesized and amplified from 45 ng of RNA using the Ovation Pico WTA System V2 kit (Nugen) according to the manufacturer’s instructions. The resulting amplified ssDNA was purified using the QIAquick purification kit (QIAGEN, MD, USA). Total DNA concentration was measured with NanoDrop 2000 spectrophotometer (Thermo Scientific) and quality was assessed on the Bioanalyzer 2100. Five micrograms of purified ssDNA were enzymatically fragmented into 50–100 bp fragments and biotin-labeled with the Encore Biotin Module kit from Nugen according to the manufacturer’s instructions. The resulting target was mixed with standard hybridization controls and B2 oligonucleotides following supplier recommendations. The hybridization cocktail was heat-denatured at 95°C for 2 min, incubated at 50°C for 5 min, and centrifuged at 16,000 × <italic>g</italic> for 5 min to pellet the residual salts. HERV-V3 microarrays were pre-hybridized with 200 μl of hybridization buffer and placed under stirring (60 rpm) in an oven at 50°C for 10 min. Hybridization buffer was then replaced by denatured hybridization cocktail. Hybridization was performed at 50°C for 18 hr in the oven under constant stirring (60 rpm). Washing and staining were carried out according to the manufacturer’s protocol, using a fluidic station (GeneChip fluidic station 450, Affymetrix). Arrays were finally scanned using a fluorometric scanner (GeneChip scanner 3000 7G, Affymetrix). Biotin purification, hybridization, and reading steps were performed by Sampled (Piscataway, NJ 08854, USA). Overall, 1,397,352 probes were detected, the vast majority of them corresponding to HERV (1,290,800 probesets), followed by genes (103,724 probesets), and LINE-1 (2828 probesets).</p></sec><sec id="s4-4"><title>Identification of DE HERV and genes</title><p>All bioinformatic analyses were performed with RStudio software version 4.2.1. Microarray CEL files were processed and analyzed using R oligo package (<xref ref-type="bibr" rid="bib13">Carvalho and Irizarry, 2010</xref>). Data were normalized, adjusted for background noise, and summarized using the RMA (Robust Multi-Array) algorithm. DE analysis was performed using limma R package (<xref ref-type="bibr" rid="bib68">Ritchie et al., 2015</xref>), considering DE those probes with a Benjamini–Hochberg adjusted p-value (FDR) <italic>&lt;</italic>0.1 and an absolute log<sub>2</sub> fold-change &gt;1. The analysis results were presented in volcano plots using EnhancedVolcano R package (<xref ref-type="bibr" rid="bib6">Blighe et al., 2022</xref>).</p></sec><sec id="s4-5"><title>Clustering analysis</title><p>DE HERV or genes (FDR &lt;0.1 and |log<sub>2</sub>FC|&gt;1) were used to perform clustering analysis. PCA was performed to analyze the behavior of samples under study based on DE HERV expression profiles by using factoextra R package (<xref ref-type="bibr" rid="bib37">Kassambara and Mundt, 2025</xref>). Samples were plotted according to the first two PCA principal components and the contribution of variables to each of the principal components was represented in barplots. Scaled expression data of DE HERV or gene probesets were used to cluster samples and probes. Data were represented in heatmap plots by using pheatmap R package (<xref ref-type="bibr" rid="bib41">Kolde et al., 2018</xref>). Rows and columns were clustered using Euclidean and Pearson correlation distances, respectively. HERV clusters were visually identified based on heatmap results and extracted from dendrograms using the pheatmap implemented function. Mean probe expression by group was calculated for all probes encompassed in each cluster and their distribution and expression level were visualized by box and violin plots. Average-linkage agglomerative hierarchical clustering with Pearson correlation distance was performed on normalized expression data to identify modules of HERV and genes with correlated expression patterns across samples. Modules of HERV–genes were produced by applying a dynamic tree cut of dendrograms using a minimum cluster size of 110 HERV or genes, as described by <xref ref-type="bibr" rid="bib56">Marston et al., 2021</xref>.</p></sec><sec id="s4-6"><title>Enrichment analysis</title><p>Microarray probes were annotated based on the HERV-V3 annotation file kindly provided by bioMérieux, allowing retrieval of HERV subdomain (gag, pol, env, or LTR), family, and genomic location of each probe. Family group information for solitary LTR probes was added based on Dfam and EnHERV databases. Original hg37 HERV-V3 coordinates were converted into hg38 genomic coordinates by using UCSC LiftOver tool (<xref ref-type="bibr" rid="bib44">Kuhn et al., 2013</xref>) and the corresponding chromosome band information was added. The genomic context of the HERV loci was assessed with Goldmine R package (<xref ref-type="bibr" rid="bib5">Bhasin and Ting, 2016</xref>). Enrichment analysis for HERV family, HERV subdomain, and genomic context was performed for the HERV encompassed in each cluster by comparing their frequency in the cluster to their corresponding on hg38 genomic data according to HERV-V3 microarray annotation (<xref ref-type="bibr" rid="bib3">Becker et al., 2017</xref>). The frequency of families, HERV subdomains, and genomic context (intron, exon, intergenic, promoter, or 3′ end) for the DE HERV encompassed in each cluster and in the overall hg38 genomic data were represented as stacked bar plots with ggplot2 R package (<xref ref-type="bibr" rid="bib80">Wickham, 2016</xref>). To assess for TFBS enrichment, the ReMapEnrich Shiny 1.4 web interface was used providing DE HERV loci genomic coordinates as input. Enriched TFBS were represented as a heatmap using pheatmap R package (<xref ref-type="bibr" rid="bib41">Kolde et al., 2018</xref>), with colors defining modules in which the enrichment was found, and no enrichments were shown as blank.</p></sec><sec id="s4-7"><title>Overrepresentation functional analysis</title><p>Genes encompassed in modules identified by hierarchical clustering as well as TF binding to identified enriched TFBS in HERV of each module were functionally analyzed by GO using the R package clusterProfiler (<xref ref-type="bibr" rid="bib84">Wu et al., 2021</xref>) with an adjusted p-value cutoff of 0.05. For each module, the top 5 GO terms as ranked by increasing adjusted p-value were visualized in a heatmap using pheatmap R package (<xref ref-type="bibr" rid="bib41">Kolde et al., 2018</xref>). Statistical significance of each GO term as adjusted p-values was represented by a color gradient, with darker colors representing more significant terms in the module. Terms sharing significant overrepresentation in other modules (adjusted p &lt; 0.05) were colored on heatmaps accordingly.</p></sec><sec id="s4-8"><title>Evaluation of overlaps between HERV and gene sequences</title><p>Genomic coordinates of HERV and genes encompassed in each module were transformed to genomic range objects (Granges) using the GenomicRanges R package (<xref ref-type="bibr" rid="bib48">Lawrence et al., 2013</xref>). They were subsequently plotted over a linear chromosomal representation with karyoploteR package (<xref ref-type="bibr" rid="bib25">Gel and Serra, 2017</xref>), which displays the density of sequences throughout chromosomes. The genomic distance between HERV and genes in the same module was determined with a specific function included in GenomicRanges package and displayed as density plots.</p></sec><sec id="s4-9"><title>Measurement of immune cell relative amounts</title><p>Digital cytometry analysis was performed with CIBERSORTx (<xref ref-type="bibr" rid="bib63">Newman et al., 2019</xref>) software on normalized non-logarithmic gene expression data for all samples. The default LM22 leukocyte gene signature matrix (<xref ref-type="bibr" rid="bib62">Newman et al., 2015</xref>) was used as a reference. LM22 was generated using Affymetrix HGU133A microarray data distinguishing 22 human hematopoietic cell phenotypes, including different types of T cells, B cells (naïve and memory), plasma cells, NK cells, monocytes, dendritic cells, and some myeloid subsets (<xref ref-type="bibr" rid="bib62">Newman et al., 2015</xref>). Output results were visually inspected for potential differences in immune cell counts and significant differences were assessed by Welch’s <italic>t</italic>-test with adjusted p-value &lt;0.05 from specific immune cell types. Results were plotted as violin plots.</p></sec><sec id="s4-10"><title>Trait-measure and symptom association</title><p>For each module extracted by hierarchical clustering the eigengenes were calculated with the use of the function moduleEigengenes implemented in WGCNA package (<xref ref-type="bibr" rid="bib47">Langfelder and Horvath, 2008</xref>). A matrix of normalized expression data and a list assigning each sequence to each module was provided as input. Calculated module eigengenes were then correlated to external microarray data, including immune cell proportion values provided by CIBERSORTx, questionnaire scores for FIQ, MFI, and SF-36, or the clinical diagnosis. This last variable was binarized with the use of binarizeCategorialColumns. Results were plotted by using pheatmap package (<xref ref-type="bibr" rid="bib41">Kolde et al., 2018</xref>) with boxes showing Pearson correlation values and associated p-values between gene expression levels of each module and the disease trait. A correlation value of 1 (orange or green) and –1 (blue) were used to quantify the strongest positive and negative correlations, respectively, while 0 (white) was assigned for no correlation.</p></sec><sec id="s4-11"><title>Real-time quantitative polymerase chain reaction</title><p>DE of specific HERV sequences was validated using the same RNA samples analyzed by microarray (<italic>n</italic> = 8 controls, <italic>n</italic> = 8 ME/CFS, <italic>n</italic> = 7 FM, and <italic>n</italic> = 14 co-diagnosed). Reverse transcription was performed using High-Capacity cDNA reverse Transcription kit (Applied Biosystems, Waltham, MA, USA, cat. 4308228), with 1 µg of total RNA according to the manufacturer’s guidelines. cDNAs were used for real-time PCR using PowerUP Sybr Green Master Mix (Applied Biosystems, cat. 100029283) and a Lightcycler LC480 instrument (Roche, Penzberg, Germany). Standard amplification conditions were applied, including a single hotstart polymerase preactivation cycle at 94°C for 15 min, up to 45 amplification cycles, each one consisting of three steps: denaturation at 95°C for 15 s, annealing at 60°C for 30 s, and extension at 70°C for 30 s. Sequences of specific primers used are detailed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1H</xref>. GAPDH levels were used for relative quantification of the RNAs amplified, and 2−∆Ct analysis to calculate expression was applied.</p></sec><sec id="s4-12"><title>Statistical analysis</title><p>All statistical analyses were done in R v4.2.1. Data distributions were tested for normality. Normally distributed data were tested using two-tailed unpaired Student’s <italic>t</italic>-tests; non-normal data were analyzed with non-parametric statistical test, as detailed. For enrichment analyses, we used a Fisher’s exact test to calculate p-value, considering enriched in the provided list if an adjusted p-value (FDR) was less than 0.05. We chose to use Fisher’s exact test in the analysis of contingency tables to compare ME/CFS and healthy group, as it is more appropriate for small sample sizes in comparison to the chi-square test or <italic>G</italic>-test of independence.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study has been performed in accordance with the Declaration of Helsinki. It was approved by the Public Health Research Ethics Committee DGSP-CSISP of Valencia, núm. 20190301/12, Valencia, Spain. All participants signed an informed consent to participate in this study.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-104441-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Raw, processed, and complementary data.</title><p>(<bold>A</bold>) Itemized participant demographics and health status assessment with FIQ, MFI and SF-36 questionnaires. (<bold>B</bold>) Statistical analysis of participant demographics and health status assessment with FIQ, MFI and SF-36 questionnaires. (<bold>C</bold>) Differentially expressed HERV. (<bold>D</bold>) Patient health status assessment with FIQ, MFI, and SF-36 questionnaires separating ME/CFS into two subgroups. (<bold>E</bold>) Relative contribution of HERV families to each cluster. (<bold>F</bold>) Differentially expressed genes. (<bold>G</bold>) Genomic distance between correlated HERVs and genes in each module. (<bold>H</bold>) Primers for RT-qPCR validation.</p></caption><media xlink:href="elife-104441-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data associated with the study are available in the paper or supplementary materials, except for HERV-V3 microarray annotation provided by bioMérieux under material transfer agreement. Microarray data is available at GSE269047 from the NCBI GEO database.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Giménez-Orenga</surname><given-names>K</given-names></name><name><surname>Martín-Martínez</surname><given-names>E</given-names></name><name><surname>Nathanson</surname><given-names>L</given-names></name><name><surname>Oltra</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269047">GSE269047</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We particularly thank all the patients who participated in the study and Dr. Vicente Serra (Umivale, Valencia, Spain) for his help in the recruitment of healthy volunteers. We also acknowledge bioMérieux (Ain, France) for allowing the use of their custom-made HERV-V3 high-density microarrays and Sampled LTD (Piscataway, NJ, USA) for assisting us in the analysis by microarray. This study was funded by an ME Research UK (SCIO charity number SC036942) grant, and by Generalitat Valenciana CIAICO/2021/103 grant to EO. KG-O is supported by the Generalitat Valenciana ACIF2021/179 grant. Funders were not involved in any of the research stages.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbi</surname><given-names>B</given-names></name><name><surname>Natelson</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the “single syndrome” hypothesis</article-title><source>QJM</source><volume>106</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hcs156</pub-id><pub-id pub-id-type="pmid">22927538</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>L</given-names></name><name><surname>Bested</surname><given-names>AC</given-names></name><name><surname>Bonilla</surname><given-names>HF</given-names></name><name><surname>Chheda</surname><given-names>BV</given-names></name><name><surname>Chu</surname><given-names>L</given-names></name><name><surname>Curtin</surname><given-names>JM</given-names></name><name><surname>Dempsey</surname><given-names>TT</given-names></name><name><surname>Dimmock</surname><given-names>ME</given-names></name><name><surname>Dowell</surname><given-names>TG</given-names></name><name><surname>Felsenstein</surname><given-names>D</given-names></name><name><surname>Kaufman</surname><given-names>DL</given-names></name><name><surname>Klimas</surname><given-names>NG</given-names></name><name><surname>Komaroff</surname><given-names>AL</given-names></name><name><surname>Lapp</surname><given-names>CW</given-names></name><name><surname>Levine</surname><given-names>SM</given-names></name><name><surname>Montoya</surname><given-names>JG</given-names></name><name><surname>Natelson</surname><given-names>BH</given-names></name><name><surname>Peterson</surname><given-names>DL</given-names></name><name><surname>Podell</surname><given-names>RN</given-names></name><name><surname>Rey</surname><given-names>IR</given-names></name><name><surname>Ruhoy</surname><given-names>IS</given-names></name><name><surname>Vera-Nunez</surname><given-names>MA</given-names></name><name><surname>Yellman</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Myalgic encephalomyelitis/chronic fatigue syndrome: Essentials of diagnosis and management</article-title><source>Mayo Clinic Proceedings</source><volume>96</volume><fpage>2861</fpage><lpage>2878</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2021.07.004</pub-id><pub-id pub-id-type="pmid">34454716</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Pérot</surname><given-names>P</given-names></name><name><surname>Cheynet</surname><given-names>V</given-names></name><name><surname>Oriol</surname><given-names>G</given-names></name><name><surname>Mugnier</surname><given-names>N</given-names></name><name><surname>Mommert</surname><given-names>M</given-names></name><name><surname>Tabone</surname><given-names>O</given-names></name><name><surname>Textoris</surname><given-names>J</given-names></name><name><surname>Veyrieras</surname><given-names>JB</given-names></name><name><surname>Mallet</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A comprehensive hybridization model allows whole HERV transcriptome profiling using high density microarray</article-title><source>BMC Genomics</source><volume>18</volume><elocation-id>286</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-017-3669-7</pub-id><pub-id pub-id-type="pmid">28390408</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergallo</surname><given-names>M</given-names></name><name><surname>Mareschi</surname><given-names>K</given-names></name><name><surname>Montanari</surname><given-names>P</given-names></name><name><surname>Calvi</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>M</given-names></name><name><surname>Bini</surname><given-names>I</given-names></name><name><surname>Daprà</surname><given-names>V</given-names></name><name><surname>Galliano</surname><given-names>I</given-names></name><name><surname>Fagioli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human endogenous retrovirus, HERV-P and HERV-R in pediatric leukemia patients</article-title><source>Journal of Hematopathology</source><volume>12</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s12308-019-00352-0</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhasin</surname><given-names>JM</given-names></name><name><surname>Ting</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Goldmine integrates information placing genomic ranges into meaningful biological contexts</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>5550</fpage><lpage>5556</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw477</pub-id><pub-id pub-id-type="pmid">27257071</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Blighe</surname><given-names>K</given-names></name><name><surname>Rana</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling</data-title><version designator="ab0428e">ab0428e</version><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/kevinblighe/EnhancedVolcano">https://github.com/kevinblighe/EnhancedVolcano</ext-link></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdan</surname><given-names>L</given-names></name><name><surname>Barreiro</surname><given-names>L</given-names></name><name><surname>Bourque</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transposable elements have contributed human regulatory regions that are activated upon bacterial infection</article-title><source>Philosophical Transactions of the Royal Society B</source><volume>375</volume><elocation-id>20190332</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2019.0332</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenu</surname><given-names>EW</given-names></name><name><surname>van Driel</surname><given-names>ML</given-names></name><name><surname>Staines</surname><given-names>DR</given-names></name><name><surname>Ashton</surname><given-names>KJ</given-names></name><name><surname>Ramos</surname><given-names>SB</given-names></name><name><surname>Keane</surname><given-names>J</given-names></name><name><surname>Klimas</surname><given-names>NG</given-names></name><name><surname>Marshall-Gradisnik</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis</article-title><source>Journal of Translational Medicine</source><volume>9</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-9-81</pub-id><pub-id pub-id-type="pmid">21619669</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenu</surname><given-names>EW</given-names></name><name><surname>Huth</surname><given-names>TK</given-names></name><name><surname>Hardcastle</surname><given-names>SL</given-names></name><name><surname>Fuller</surname><given-names>K</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Johnston</surname><given-names>S</given-names></name><name><surname>Ramos</surname><given-names>SB</given-names></name><name><surname>Staines</surname><given-names>DR</given-names></name><name><surname>Marshall-Gradisnik</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis</article-title><source>International Immunology</source><volume>26</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxt068</pub-id><pub-id pub-id-type="pmid">24343819</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burckhardt</surname><given-names>CS</given-names></name><name><surname>Clark</surname><given-names>SR</given-names></name><name><surname>Bennett</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The fibromyalgia impact questionnaire: development and validation</article-title><source>The Journal of Rheumatology</source><volume>18</volume><fpage>728</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">1865419</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carruthers</surname><given-names>BM</given-names></name><name><surname>Jain</surname><given-names>AK</given-names></name><name><surname>De Meirleir</surname><given-names>KL</given-names></name><name><surname>Peterson</surname><given-names>DL</given-names></name><name><surname>Klimas</surname><given-names>NG</given-names></name><name><surname>Lerner</surname><given-names>AM</given-names></name><name><surname>Bested</surname><given-names>AC</given-names></name><name><surname>Flor-Henry</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>P</given-names></name><name><surname>Powles</surname><given-names>ACP</given-names></name><name><surname>Sherkey</surname><given-names>JA</given-names></name><name><surname>van de Sande</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</article-title><source>Journal of Chronic Fatigue Syndrome</source><volume>11</volume><fpage>7</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1300/J092v11n01_02</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carruthers</surname><given-names>BM</given-names></name><name><surname>van de Sande</surname><given-names>MI</given-names></name><name><surname>De Meirleir</surname><given-names>KL</given-names></name><name><surname>Klimas</surname><given-names>NG</given-names></name><name><surname>Broderick</surname><given-names>G</given-names></name><name><surname>Mitchell</surname><given-names>T</given-names></name><name><surname>Staines</surname><given-names>D</given-names></name><name><surname>Powles</surname><given-names>ACP</given-names></name><name><surname>Speight</surname><given-names>N</given-names></name><name><surname>Vallings</surname><given-names>R</given-names></name><name><surname>Bateman</surname><given-names>L</given-names></name><name><surname>Baumgarten-Austrheim</surname><given-names>B</given-names></name><name><surname>Bell</surname><given-names>DS</given-names></name><name><surname>Carlo-Stella</surname><given-names>N</given-names></name><name><surname>Chia</surname><given-names>J</given-names></name><name><surname>Darragh</surname><given-names>A</given-names></name><name><surname>Jo</surname><given-names>D</given-names></name><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Light</surname><given-names>AR</given-names></name><name><surname>Marshall-Gradisnik</surname><given-names>S</given-names></name><name><surname>Mena</surname><given-names>I</given-names></name><name><surname>Mikovits</surname><given-names>JA</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Murovska</surname><given-names>M</given-names></name><name><surname>Pall</surname><given-names>ML</given-names></name><name><surname>Stevens</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Myalgic encephalomyelitis: International consensus criteria</article-title><source>Journal of Internal Medicine</source><volume>270</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2011.02428.x</pub-id><pub-id pub-id-type="pmid">21777306</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>BS</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A framework for oligonucleotide microarray preprocessing</article-title><source>Bioinformatics</source><volume>26</volume><fpage>2363</fpage><lpage>2367</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq431</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro-Marrero</surname><given-names>J</given-names></name><name><surname>Faro</surname><given-names>M</given-names></name><name><surname>Aliste</surname><given-names>L</given-names></name><name><surname>Sáez-Francàs</surname><given-names>N</given-names></name><name><surname>Calvo</surname><given-names>N</given-names></name><name><surname>Martínez-Martínez</surname><given-names>A</given-names></name><name><surname>de Sevilla</surname><given-names>TF</given-names></name><name><surname>Alegre</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comorbidity in chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide population-based cohort study</article-title><source>Psychosomatics</source><volume>58</volume><fpage>533</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/j.psym.2017.04.010</pub-id><pub-id pub-id-type="pmid">28596045</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charvet</surname><given-names>B</given-names></name><name><surname>Brunel</surname><given-names>J</given-names></name><name><surname>Pierquin</surname><given-names>J</given-names></name><name><surname>Iampietro</surname><given-names>M</given-names></name><name><surname>Decimo</surname><given-names>D</given-names></name><name><surname>Queruel</surname><given-names>N</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>del M Encabo-Berzosa</surname><given-names>M</given-names></name><name><surname>Arenaz</surname><given-names>I</given-names></name><name><surname>Marmolejo</surname><given-names>TP</given-names></name><name><surname>Gonzalez</surname><given-names>AI</given-names></name><name><surname>Maldonado</surname><given-names>AC</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Küry</surname><given-names>P</given-names></name><name><surname>Flores-Rivera</surname><given-names>J</given-names></name><name><surname>Torres-Ruiz</surname><given-names>F</given-names></name><name><surname>Avila-Rios</surname><given-names>S</given-names></name><name><surname>Salgado Montes de Oca</surname><given-names>G</given-names></name><name><surname>Schoorlemmer</surname><given-names>J</given-names></name><name><surname>Perron</surname><given-names>H</given-names></name><name><surname>Horvat</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients</article-title><source>iScience</source><volume>26</volume><elocation-id>106604</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2023.106604</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>L</given-names></name><name><surname>Valencia</surname><given-names>IJ</given-names></name><name><surname>Garvert</surname><given-names>DW</given-names></name><name><surname>Montoya</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Onset patterns and course of myalgic encephalomyelitis/chronic fatigue syndrome</article-title><source>Frontiers in Pediatrics</source><volume>7</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2019.00012</pub-id><pub-id pub-id-type="pmid">30805319</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clauw</surname><given-names>DJ</given-names></name><name><surname>Calabrese</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Rheumatology and Long COVID: lessons from the study of fibromyalgia</article-title><source>Annals of the Rheumatic Diseases</source><volume>83</volume><fpage>136</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1136/ard-2023-224250</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curriu</surname><given-names>M</given-names></name><name><surname>Carrillo</surname><given-names>J</given-names></name><name><surname>Massanella</surname><given-names>M</given-names></name><name><surname>Rigau</surname><given-names>J</given-names></name><name><surname>Alegre</surname><given-names>J</given-names></name><name><surname>Puig</surname><given-names>J</given-names></name><name><surname>Garcia-Quintana</surname><given-names>AM</given-names></name><name><surname>Castro-Marrero</surname><given-names>J</given-names></name><name><surname>Negredo</surname><given-names>E</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>Cabrera</surname><given-names>C</given-names></name><name><surname>Blanco</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome</article-title><source>Journal of Translational Medicine</source><volume>11</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-11-68</pub-id><pub-id pub-id-type="pmid">23514202</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolei</surname><given-names>A</given-names></name><name><surname>Garson</surname><given-names>JA</given-names></name><name><surname>Arru</surname><given-names>G</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Germi</surname><given-names>R</given-names></name><name><surname>Marche</surname><given-names>PN</given-names></name><name><surname>Perron</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Multiple sclerosis-associated retrovirus and related human endogenous retrovirus-W in patients with multiple sclerosis</article-title><source>Journal of Neuroimmunology</source><volume>266</volume><fpage>87</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.11.009</pub-id><pub-id pub-id-type="pmid">24355750</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dopkins</surname><given-names>N</given-names></name><name><surname>O’Mara</surname><given-names>MM</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Marston</surname><given-names>JL</given-names></name><name><surname>Bendall</surname><given-names>ML</given-names></name><name><surname>Nixon</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>How human endogenous retroviruses interact with the microbiota in health and disease</article-title><source>Trends in Microbiology</source><volume>30</volume><fpage>812</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2022.05.011</pub-id><pub-id pub-id-type="pmid">35672223</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaton-Fitch</surname><given-names>N</given-names></name><name><surname>du Preez</surname><given-names>S</given-names></name><name><surname>Cabanas</surname><given-names>H</given-names></name><name><surname>Staines</surname><given-names>D</given-names></name><name><surname>Marshall-Gradisnik</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome</article-title><source>Systematic Reviews</source><volume>8</volume><elocation-id>279</elocation-id><pub-id pub-id-type="doi">10.1186/s13643-019-1202-6</pub-id><pub-id pub-id-type="pmid">31727160</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fay</surname><given-names>NS</given-names></name><name><surname>Larson</surname><given-names>EC</given-names></name><name><surname>Jameson</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chronic inflammation and γδ T cells</article-title><source>Frontiers in Immunology</source><volume>7</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2016.00210</pub-id><pub-id pub-id-type="pmid">27303404</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>R</given-names></name><name><surname>Grandi</surname><given-names>N</given-names></name><name><surname>Tramontano</surname><given-names>E</given-names></name><name><surname>Dieci</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Retrotransposons as drivers of mammalian brain evolution</article-title><source>Life</source><volume>11</volume><elocation-id>376</elocation-id><pub-id pub-id-type="doi">10.3390/life11050376</pub-id><pub-id pub-id-type="pmid">33922141</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furness</surname><given-names>PJ</given-names></name><name><surname>Vogt</surname><given-names>K</given-names></name><name><surname>Ashe</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>Haywood-Small</surname><given-names>S</given-names></name><name><surname>Lawson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>What causes fibromyalgia? An online survey of patient perspectives</article-title><source>Health Psychology Open</source><volume>5</volume><elocation-id>2055102918802683</elocation-id><pub-id pub-id-type="doi">10.1177/2055102918802683</pub-id><pub-id pub-id-type="pmid">30275965</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gel</surname><given-names>B</given-names></name><name><surname>Serra</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data</article-title><source>Bioinformatics</source><volume>33</volume><fpage>3088</fpage><lpage>3090</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx346</pub-id><pub-id pub-id-type="pmid">28575171</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giménez-Orenga</surname><given-names>K</given-names></name><name><surname>Oltra</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human endogenous retrovirus as therapeutic targets in neurologic disease</article-title><source>Pharmaceuticals</source><volume>14</volume><elocation-id>495</elocation-id><pub-id pub-id-type="doi">10.3390/ph14060495</pub-id><pub-id pub-id-type="pmid">34073730</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giménez-Orenga</surname><given-names>K</given-names></name><name><surname>Pierquin</surname><given-names>J</given-names></name><name><surname>Brunel</surname><given-names>J</given-names></name><name><surname>Charvet</surname><given-names>B</given-names></name><name><surname>Martín-Martínez</surname><given-names>E</given-names></name><name><surname>Perron</surname><given-names>H</given-names></name><name><surname>Oltra</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>1020064</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1020064</pub-id><pub-id pub-id-type="pmid">36389746</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodchild</surname><given-names>NL</given-names></name><name><surname>Wilkinson</surname><given-names>DA</given-names></name><name><surname>Mager</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Recent evolutionary expansion of a subfamily of RTVL-H human endogenous retrovirus-like elements</article-title><source>Virology</source><volume>196</volume><fpage>778</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1006/viro.1993.1535</pub-id><pub-id pub-id-type="pmid">8372448</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groven</surname><given-names>N</given-names></name><name><surname>Reitan</surname><given-names>SK</given-names></name><name><surname>Fors</surname><given-names>EA</given-names></name><name><surname>Guzey</surname><given-names>IC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Kynurenine metabolites and ratios differ between Chronic Fatigue Syndrome, Fibromyalgia, and healthy controls</article-title><source>Psychoneuroendocrinology</source><volume>131</volume><elocation-id>105287</elocation-id><pub-id pub-id-type="doi">10.1016/j.psyneuen.2021.105287</pub-id><pub-id pub-id-type="pmid">34090138</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruchot</surname><given-names>J</given-names></name><name><surname>Lewen</surname><given-names>I</given-names></name><name><surname>Dietrich</surname><given-names>M</given-names></name><name><surname>Reiche</surname><given-names>L</given-names></name><name><surname>Sindi</surname><given-names>M</given-names></name><name><surname>Hecker</surname><given-names>C</given-names></name><name><surname>Herrero</surname><given-names>F</given-names></name><name><surname>Charvet</surname><given-names>B</given-names></name><name><surname>Weber-Stadlbauer</surname><given-names>U</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name><name><surname>Albrecht</surname><given-names>P</given-names></name><name><surname>Perron</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>U</given-names></name><name><surname>Küry</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2308187120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2308187120</pub-id><pub-id pub-id-type="pmid">37695891</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Identification and characterization of endogenous retroviruses upon SARS-CoV-2 infection</article-title><source>Frontiers in Immunology</source><volume>15</volume><elocation-id>1294020</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1294020</pub-id><pub-id pub-id-type="pmid">38646531</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>JE</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Jakob</surname><given-names>R</given-names></name><name><surname>Chute</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ICD-11: an international classification of diseases for the twenty-first century</article-title><source>BMC Medical Informatics and Decision Making</source><volume>21</volume><elocation-id>206</elocation-id><pub-id pub-id-type="doi">10.1186/s12911-021-01534-6</pub-id><pub-id pub-id-type="pmid">34753471</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriques</surname><given-names>A</given-names></name><name><surname>Teixeira</surname><given-names>L</given-names></name><name><surname>Inês</surname><given-names>L</given-names></name><name><surname>Carvalheiro</surname><given-names>T</given-names></name><name><surname>Gonçalves</surname><given-names>A</given-names></name><name><surname>Martinho</surname><given-names>A</given-names></name><name><surname>Pais</surname><given-names>ML</given-names></name><name><surname>da Silva</surname><given-names>JAP</given-names></name><name><surname>Paiva</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>NK cells dysfunction in systemic lupus erythematosus: relation to disease activity</article-title><source>Clinical Rheumatology</source><volume>32</volume><fpage>805</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1007/s10067-013-2176-8</pub-id><pub-id pub-id-type="pmid">23377197</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermetz</surname><given-names>KE</given-names></name><name><surname>Surti</surname><given-names>U</given-names></name><name><surname>Cody</surname><given-names>JD</given-names></name><name><surname>Rudd</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A recurrent translocation is mediated by homologous recombination between HERV-H elements</article-title><source>Molecular Cytogenetics</source><volume>5</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1186/1755-8166-5-6</pub-id><pub-id pub-id-type="pmid">22260357</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>J</given-names></name><name><surname>Sugimoto</surname><given-names>R</given-names></name><name><surname>Nakaoka</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Hayano</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Systematic identification and characterization of regulatory elements derived from human endogenous retroviruses</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006883</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006883</pub-id><pub-id pub-id-type="pmid">28700586</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jason</surname><given-names>LA</given-names></name><name><surname>Dorri</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ME/CFS and post-exertional malaise among patients with long COVID</article-title><source>Neurology International</source><volume>15</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3390/neurolint15010001</pub-id><pub-id pub-id-type="pmid">36648965</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kassambara</surname><given-names>A</given-names></name><name><surname>Mundt</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Factoextra: extract and visualize the results of multivariate data analyses</data-title><version designator="1.0.6">1.0.6</version><source>CRAN_Status_Badge</source><ext-link ext-link-type="uri" xlink:href="https://rpkgs.datanovia.com/factoextra/index.html">https://rpkgs.datanovia.com/factoextra/index.html</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassiotis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The immunological conundrum of endogenous retroelements</article-title><source>Annual Review of Immunology</source><volume>41</volume><fpage>99</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101721-033341</pub-id><pub-id pub-id-type="pmid">36630597</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khadjinova</surname><given-names>AI</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Laine</surname><given-names>A</given-names></name><name><surname>Ukadike</surname><given-names>K</given-names></name><name><surname>Eckert</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Bengtsson</surname><given-names>AA</given-names></name><name><surname>Lood</surname><given-names>C</given-names></name><name><surname>Mustelin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Autoantibodies against the envelope proteins of endogenous retroviruses K102 and K108 in patients with systemic lupus erythematosus correlate with active disease</article-title><source>Clinical and Experimental Rheumatology</source><volume>40</volume><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.55563/clinexprheumatol/2kg1d8</pub-id><pub-id pub-id-type="pmid">34665695</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Ahn</surname><given-names>CW</given-names></name><name><surname>Nam</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes</article-title><source>Journal of Diabetes Investigation</source><volume>10</volume><fpage>1223</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1111/jdi.13002</pub-id><pub-id pub-id-type="pmid">30618112</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kolde</surname><given-names>R</given-names></name><name><surname>Lizee</surname><given-names>A</given-names></name><name><surname>Metsalu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Pheatmap: pretty heatmaps</data-title><version designator="b333453">b333453</version><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/raivokolde/pheatmap">https://github.com/raivokolde/pheatmap</ext-link></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komaroff</surname><given-names>AL</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature</article-title><source>Frontiers in Medicine</source><volume>10</volume><elocation-id>1187163</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1187163</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>D</given-names></name><name><surname>Schichel</surname><given-names>T</given-names></name><name><surname>Förster</surname><given-names>M</given-names></name><name><surname>Tzekova</surname><given-names>N</given-names></name><name><surname>Bernard</surname><given-names>C</given-names></name><name><surname>van der Valk</surname><given-names>P</given-names></name><name><surname>van Horssen</surname><given-names>J</given-names></name><name><surname>Hartung</surname><given-names>H-P</given-names></name><name><surname>Perron</surname><given-names>H</given-names></name><name><surname>Küry</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation</article-title><source>Annals of Neurology</source><volume>74</volume><fpage>721</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1002/ana.23970</pub-id><pub-id pub-id-type="pmid">23836485</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>RM</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The UCSC genome browser and associated tools</article-title><source>Briefings in Bioinformatics</source><volume>14</volume><fpage>144</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs038</pub-id><pub-id pub-id-type="pmid">22908213</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulski</surname><given-names>JK</given-names></name><name><surname>Gaudieri</surname><given-names>S</given-names></name><name><surname>Inoko</surname><given-names>H</given-names></name><name><surname>Dawkins</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Comparison between two human endogenous retrovirus (HERV)-Rich regions within the major histocompatibility complex</article-title><source>Journal of Molecular Evolution</source><volume>48</volume><fpage>675</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1007/PL00006511</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Linton</surname><given-names>LM</given-names></name><name><surname>Birren</surname><given-names>B</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Zody</surname><given-names>MC</given-names></name><name><surname>Baldwin</surname><given-names>J</given-names></name><name><surname>Devon</surname><given-names>K</given-names></name><name><surname>Dewar</surname><given-names>K</given-names></name><name><surname>Doyle</surname><given-names>M</given-names></name><name><surname>FitzHugh</surname><given-names>W</given-names></name><name><surname>Funke</surname><given-names>R</given-names></name><name><surname>Gage</surname><given-names>D</given-names></name><name><surname>Harris</surname><given-names>K</given-names></name><name><surname>Heaford</surname><given-names>A</given-names></name><name><surname>Howland</surname><given-names>J</given-names></name><name><surname>Kann</surname><given-names>L</given-names></name><name><surname>Lehoczky</surname><given-names>J</given-names></name><name><surname>LeVine</surname><given-names>R</given-names></name><name><surname>McEwan</surname><given-names>P</given-names></name><name><surname>McKernan</surname><given-names>K</given-names></name><name><surname>Meldrim</surname><given-names>J</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Miranda</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>W</given-names></name><name><surname>Naylor</surname><given-names>J</given-names></name><name><surname>Raymond</surname><given-names>C</given-names></name><name><surname>Rosetti</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Sheridan</surname><given-names>A</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Stange-Thomann</surname><given-names>N</given-names></name><name><surname>Stojanovic</surname><given-names>N</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Wyman</surname><given-names>D</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Sulston</surname><given-names>J</given-names></name><name><surname>Ainscough</surname><given-names>R</given-names></name><name><surname>Beck</surname><given-names>S</given-names></name><name><surname>Bentley</surname><given-names>D</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name><name><surname>Clee</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>N</given-names></name><name><surname>Coulson</surname><given-names>A</given-names></name><name><surname>Deadman</surname><given-names>R</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Dunham</surname><given-names>A</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>French</surname><given-names>L</given-names></name><name><surname>Grafham</surname><given-names>D</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Hubbard</surname><given-names>T</given-names></name><name><surname>Humphray</surname><given-names>S</given-names></name><name><surname>Hunt</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Lloyd</surname><given-names>C</given-names></name><name><surname>McMurray</surname><given-names>A</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Mercer</surname><given-names>S</given-names></name><name><surname>Milne</surname><given-names>S</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Mungall</surname><given-names>A</given-names></name><name><surname>Plumb</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>M</given-names></name><name><surname>Shownkeen</surname><given-names>R</given-names></name><name><surname>Sims</surname><given-names>S</given-names></name><name><surname>Waterston</surname><given-names>RH</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Hillier</surname><given-names>LW</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Fulton</surname><given-names>LA</given-names></name><name><surname>Chinwalla</surname><given-names>AT</given-names></name><name><surname>Pepin</surname><given-names>KH</given-names></name><name><surname>Gish</surname><given-names>WR</given-names></name><name><surname>Chissoe</surname><given-names>SL</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Delehaunty</surname><given-names>KD</given-names></name><name><surname>Miner</surname><given-names>TL</given-names></name><name><surname>Delehaunty</surname><given-names>A</given-names></name><name><surname>Kramer</surname><given-names>JB</given-names></name><name><surname>Cook</surname><given-names>LL</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Johnson</surname><given-names>DL</given-names></name><name><surname>Minx</surname><given-names>PJ</given-names></name><name><surname>Clifton</surname><given-names>SW</given-names></name><name><surname>Hawkins</surname><given-names>T</given-names></name><name><surname>Branscomb</surname><given-names>E</given-names></name><name><surname>Predki</surname><given-names>P</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Wenning</surname><given-names>S</given-names></name><name><surname>Slezak</surname><given-names>T</given-names></name><name><surname>Doggett</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>J-F</given-names></name><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Lucas</surname><given-names>S</given-names></name><name><surname>Elkin</surname><given-names>C</given-names></name><name><surname>Uberbacher</surname><given-names>E</given-names></name><name><surname>Frazier</surname><given-names>M</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Scherer</surname><given-names>SE</given-names></name><name><surname>Bouck</surname><given-names>JB</given-names></name><name><surname>Sodergren</surname><given-names>EJ</given-names></name><name><surname>Worley</surname><given-names>KC</given-names></name><name><surname>Rives</surname><given-names>CM</given-names></name><name><surname>Gorrell</surname><given-names>JH</given-names></name><name><surname>Metzker</surname><given-names>ML</given-names></name><name><surname>Naylor</surname><given-names>SL</given-names></name><name><surname>Kucherlapati</surname><given-names>RS</given-names></name><name><surname>Nelson</surname><given-names>DL</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name><name><surname>Sakaki</surname><given-names>Y</given-names></name><name><surname>Fujiyama</surname><given-names>A</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Yada</surname><given-names>T</given-names></name><name><surname>Toyoda</surname><given-names>A</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Kawagoe</surname><given-names>C</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Taylor</surname><given-names>T</given-names></name><name><surname>Weissenbach</surname><given-names>J</given-names></name><name><surname>Heilig</surname><given-names>R</given-names></name><name><surname>Saurin</surname><given-names>W</given-names></name><name><surname>Artiguenave</surname><given-names>F</given-names></name><name><surname>Brottier</surname><given-names>P</given-names></name><name><surname>Bruls</surname><given-names>T</given-names></name><name><surname>Pelletier</surname><given-names>E</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Wincker</surname><given-names>P</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Platzer</surname><given-names>M</given-names></name><name><surname>Nyakatura</surname><given-names>G</given-names></name><name><surname>Taudien</surname><given-names>S</given-names></name><name><surname>Rump</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name><name><surname>Doucette-Stamm</surname><given-names>L</given-names></name><name><surname>Rubenfield</surname><given-names>M</given-names></name><name><surname>Weinstock</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name><name><surname>Dubois</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Hood</surname><given-names>L</given-names></name><name><surname>Rowen</surname><given-names>L</given-names></name><name><surname>Madan</surname><given-names>A</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>RW</given-names></name><name><surname>Federspiel</surname><given-names>NA</given-names></name><name><surname>Abola</surname><given-names>AP</given-names></name><name><surname>Proctor</surname><given-names>MJ</given-names></name><name><surname>Roe</surname><given-names>BA</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Ramser</surname><given-names>J</given-names></name><name><surname>Lehrach</surname><given-names>H</given-names></name><name><surname>Reinhardt</surname><given-names>R</given-names></name><name><surname>McCombie</surname><given-names>WR</given-names></name><name><surname>de la Bastide</surname><given-names>M</given-names></name><name><surname>Dedhia</surname><given-names>N</given-names></name><name><surname>Blöcker</surname><given-names>H</given-names></name><name><surname>Hornischer</surname><given-names>K</given-names></name><name><surname>Nordsiek</surname><given-names>G</given-names></name><name><surname>Agarwala</surname><given-names>R</given-names></name><name><surname>Aravind</surname><given-names>L</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Batzoglou</surname><given-names>S</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>DG</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Cerutti</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H-C</given-names></name><name><surname>Church</surname><given-names>D</given-names></name><name><surname>Clamp</surname><given-names>M</given-names></name><name><surname>Copley</surname><given-names>RR</given-names></name><name><surname>Doerks</surname><given-names>T</given-names></name><name><surname>Eddy</surname><given-names>SR</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Furey</surname><given-names>TS</given-names></name><name><surname>Galagan</surname><given-names>J</given-names></name><name><surname>Gilbert</surname><given-names>JGR</given-names></name><name><surname>Harmon</surname><given-names>C</given-names></name><name><surname>Hayashizaki</surname><given-names>Y</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name><name><surname>Hokamp</surname><given-names>K</given-names></name><name><surname>Jang</surname><given-names>W</given-names></name><name><surname>Johnson</surname><given-names>LS</given-names></name><name><surname>Jones</surname><given-names>TA</given-names></name><name><surname>Kasif</surname><given-names>S</given-names></name><name><surname>Kaspryzk</surname><given-names>A</given-names></name><name><surname>Kennedy</surname><given-names>S</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Kitts</surname><given-names>P</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name><name><surname>Korf</surname><given-names>I</given-names></name><name><surname>Kulp</surname><given-names>D</given-names></name><name><surname>Lancet</surname><given-names>D</given-names></name><name><surname>Lowe</surname><given-names>TM</given-names></name><name><surname>McLysaght</surname><given-names>A</given-names></name><name><surname>Mikkelsen</surname><given-names>T</given-names></name><name><surname>Moran</surname><given-names>JV</given-names></name><name><surname>Mulder</surname><given-names>N</given-names></name><name><surname>Pollara</surname><given-names>VJ</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name><name><surname>Schultz</surname><given-names>J</given-names></name><name><surname>Slater</surname><given-names>G</given-names></name><name><surname>Smit</surname><given-names>AFA</given-names></name><name><surname>Stupka</surname><given-names>E</given-names></name><name><surname>Szustakowki</surname><given-names>J</given-names></name><name><surname>Thierry-Mieg</surname><given-names>D</given-names></name><name><surname>Thierry-Mieg</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Wallis</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>YI</given-names></name><name><surname>Wolfe</surname><given-names>KH</given-names></name><name><surname>Yang</surname><given-names>S-P</given-names></name><name><surname>Yeh</surname><given-names>R-F</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name><name><surname>Guyer</surname><given-names>MS</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Felsenfeld</surname><given-names>A</given-names></name><name><surname>Wetterstrand</surname><given-names>KA</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Schmutz</surname><given-names>J</given-names></name><name><surname>Dickson</surname><given-names>M</given-names></name><name><surname>Grimwood</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>DR</given-names></name><name><surname>Olson</surname><given-names>MV</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name><name><surname>Raymond</surname><given-names>C</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Kawasaki</surname><given-names>K</given-names></name><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>GA</given-names></name><name><surname>Athanasiou</surname><given-names>M</given-names></name><name><surname>Schultz</surname><given-names>R</given-names></name><name><surname>Patrinos</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>MJ</given-names></name><collab>International Human Genome Sequencing Consortium</collab><collab>Whitehead Institute for Biomedical Research, Center for Genome Research</collab><collab>The Sanger Centre</collab><collab>Washington University Genome Sequencing Center</collab><collab>US DOE Joint Genome Institute</collab><collab>Baylor College of Medicine Human Genome Sequencing Center</collab><collab>RIKEN Genomic Sciences Center</collab><collab>Genoscope and CNRS UMR-8030</collab><collab>Department of Genome Analysis, Institute of Molecular Biotechnology</collab><collab>GTC Sequencing Center</collab><collab>Beijing Genomics Institute/Human Genome Center</collab><collab>Multimegabase Sequencing Center, The Institute for Systems Biology</collab><collab>Stanford Genome Technology Center</collab><collab>University of Oklahoma’s Advanced Center for Genome Technology</collab><collab>Max Planck Institute for Molecular Genetics</collab><collab>Cold Spring Harbor Laboratory, Lita Annenberg Hazen Genome Center</collab><collab>GBF—German Research Centre for Biotechnology</collab><collab>*Genome Analysis Group</collab><collab>Scientific management: National Human Genome Research Institute, US National Institutes of Health</collab><collab>Stanford Human Genome Center</collab><collab>University of Washington Genome Center</collab><collab>Department of Molecular Biology, Keio University School of Medicine</collab><collab>University of Texas Southwestern Medical Center at Dallas</collab><collab>Office of Science, US Department of Energy</collab><collab>The Wellcome Trust</collab></person-group><year iso-8601-date="2001">2001</year><article-title>Initial sequencing and analysis of the human genome</article-title><source>Nature</source><volume>409</volume><fpage>860</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1038/35057062</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>WGCNA: an R package for weighted correlation network analysis</article-title><source>BMC Bioinformatics</source><volume>9</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id><pub-id pub-id-type="pmid">19114008</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Pagès</surname><given-names>H</given-names></name><name><surname>Aboyoun</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>MT</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Software for computing and annotating genomic ranges</article-title><source>PLOS Computational Biology</source><volume>9</volume><elocation-id>e1003118</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003118</pub-id><pub-id pub-id-type="pmid">23950696</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Light</surname><given-names>AR</given-names></name><name><surname>Bateman</surname><given-names>L</given-names></name><name><surname>Jo</surname><given-names>D</given-names></name><name><surname>Hughen</surname><given-names>RW</given-names></name><name><surname>Vanhaitsma</surname><given-names>TA</given-names></name><name><surname>White</surname><given-names>AT</given-names></name><name><surname>Light</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome</article-title><source>Journal of Internal Medicine</source><volume>271</volume><fpage>64</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2011.02405.x</pub-id><pub-id pub-id-type="pmid">21615807</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima-Junior</surname><given-names>DS</given-names></name><name><surname>Krishnamurthy</surname><given-names>SR</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>S-J</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Constantinides</surname><given-names>MG</given-names></name><name><surname>Link</surname><given-names>VM</given-names></name><name><surname>Lim</surname><given-names>AI</given-names></name><name><surname>Enamorado</surname><given-names>M</given-names></name><name><surname>Cataisson</surname><given-names>C</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Rao</surname><given-names>I</given-names></name><name><surname>Farley</surname><given-names>TK</given-names></name><name><surname>Koroleva</surname><given-names>G</given-names></name><name><surname>Attig</surname><given-names>J</given-names></name><name><surname>Yuspa</surname><given-names>SH</given-names></name><name><surname>Fischbach</surname><given-names>MA</given-names></name><name><surname>Kassiotis</surname><given-names>G</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endogenous retroviruses promote homeostatic and inflammatory responses to the microbiota</article-title><source>Cell</source><volume>184</volume><fpage>3794</fpage><lpage>3811</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.05.020</pub-id><pub-id pub-id-type="pmid">34166614</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>T</given-names></name><name><surname>Parameswaran</surname><given-names>S</given-names></name><name><surname>Ernst</surname><given-names>K</given-names></name><name><surname>Marazzi</surname><given-names>I</given-names></name><name><surname>Weirauch</surname><given-names>MT</given-names></name><name><surname>Fuxman Bass</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human Virus Transcriptional Regulators</article-title><source>Cell</source><volume>182</volume><fpage>24</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.023</pub-id><pub-id pub-id-type="pmid">32649876</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macchietto</surname><given-names>MG</given-names></name><name><surname>Langlois</surname><given-names>RA</given-names></name><name><surname>Shen</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Virus-induced transposable element expression up-regulation in human and mouse host cells</article-title><source>Life Science Alliance</source><volume>3</volume><elocation-id>e201900536</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.201900536</pub-id><pub-id pub-id-type="pmid">31964680</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mager</surname><given-names>DL</given-names></name><name><surname>Hunter</surname><given-names>DG</given-names></name><name><surname>Schertzer</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3)</article-title><source>Genomics</source><volume>59</volume><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1006/geno.1999.5877</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnus</surname><given-names>P</given-names></name><name><surname>Gunnes</surname><given-names>N</given-names></name><name><surname>Tveito</surname><given-names>K</given-names></name><name><surname>Bakken</surname><given-names>IJ</given-names></name><name><surname>Ghaderi</surname><given-names>S</given-names></name><name><surname>Stoltenberg</surname><given-names>C</given-names></name><name><surname>Hornig</surname><given-names>M</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name><name><surname>Trogstad</surname><given-names>L</given-names></name><name><surname>Håberg</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine</article-title><source>Vaccine</source><volume>33</volume><fpage>6173</fpage><lpage>6177</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.10.018</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangeney</surname><given-names>M</given-names></name><name><surname>de Parseval</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Heidmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The full-length envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties</article-title><source>The Journal of General Virology</source><volume>82</volume><fpage>2515</fpage><lpage>2518</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-82-10-2515</pub-id><pub-id pub-id-type="pmid">11562544</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marston</surname><given-names>JL</given-names></name><name><surname>Greenig</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Bendall</surname><given-names>ML</given-names></name><name><surname>Duarte</surname><given-names>RRR</given-names></name><name><surname>Feschotte</surname><given-names>C</given-names></name><name><surname>Iñiguez</surname><given-names>LP</given-names></name><name><surname>Nixon</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 infection mediates differential expression of human endogenous retroviruses and long interspersed nuclear elements</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>e147170</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.147170</pub-id><pub-id pub-id-type="pmid">34731091</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>J</given-names></name><name><surname>Takahashi Ueda</surname><given-names>M</given-names></name><name><surname>Mitsuhashi</surname><given-names>S</given-names></name><name><surname>Kochi</surname><given-names>Y</given-names></name><name><surname>Kaneko-Ishino</surname><given-names>T</given-names></name><name><surname>Ishino</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HERV-Derived <italic>Ervpb1</italic> Is conserved in simiiformes, exhibiting expression in hematopoietic cell lineages including macrophages</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>4504</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22094504</pub-id><pub-id pub-id-type="pmid">33925887</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mchorney</surname><given-names>CA</given-names></name><name><surname>Johne</surname><given-names>W</given-names></name><name><surname>Anastasiae</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The MOS 36-item short-form health survey (SF-36)</article-title><source>Medical Care</source><volume>31</volume><fpage>247</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1097/00005650-199303000-00006</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Murdjeva</surname><given-names>M</given-names></name><name><surname>Puri</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Do human endogenous retroviruses contribute to multiple sclerosis, and if so, how?</article-title><source>Molecular Neurobiology</source><volume>56</volume><fpage>2590</fpage><lpage>2605</lpage><pub-id pub-id-type="doi">10.1007/s12035-018-1255-x</pub-id><pub-id pub-id-type="pmid">30047100</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natelson</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: Definitions, similarities, and differences</article-title><source>Clinical Therapeutics</source><volume>41</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2018.12.016</pub-id><pub-id pub-id-type="pmid">30795933</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nepotchatykh</surname><given-names>E</given-names></name><name><surname>Caraus</surname><given-names>I</given-names></name><name><surname>Elremaly</surname><given-names>W</given-names></name><name><surname>Leveau</surname><given-names>C</given-names></name><name><surname>Elbakry</surname><given-names>M</given-names></name><name><surname>Godbout</surname><given-names>C</given-names></name><name><surname>Rostami-Afshari</surname><given-names>B</given-names></name><name><surname>Petre</surname><given-names>D</given-names></name><name><surname>Khatami</surname><given-names>N</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions</article-title><source>Scientific Reports</source><volume>13</volume><elocation-id>1896</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-28955-9</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AM</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hoang</surname><given-names>CD</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title><source>Nature Methods</source><volume>12</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AM</given-names></name><name><surname>Steen</surname><given-names>CB</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Chaudhuri</surname><given-names>AA</given-names></name><name><surname>Scherer</surname><given-names>F</given-names></name><name><surname>Khodadoust</surname><given-names>MS</given-names></name><name><surname>Esfahani</surname><given-names>MS</given-names></name><name><surname>Luca</surname><given-names>BA</given-names></name><name><surname>Steiner</surname><given-names>D</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Determining cell type abundance and expression from bulk tissues with digital cytometry</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>773</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0114-2</pub-id><pub-id pub-id-type="pmid">31061481</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ovejero</surname><given-names>T</given-names></name><name><surname>Sadones</surname><given-names>O</given-names></name><name><surname>Sánchez-Fito</surname><given-names>T</given-names></name><name><surname>Almenar-Pérez</surname><given-names>E</given-names></name><name><surname>Espejo</surname><given-names>JA</given-names></name><name><surname>Martín-Martínez</surname><given-names>E</given-names></name><name><surname>Nathanson</surname><given-names>L</given-names></name><name><surname>Oltra</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activation of transposable elements in immune cells of fibromyalgia patients</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>1366</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21041366</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>L</given-names></name><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Caron</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Busche</surname><given-names>S</given-names></name><name><surname>Kwan</surname><given-names>T</given-names></name><name><surname>Pastinen</surname><given-names>T</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Bourque</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conserved expression of transposon-derived non-coding transcripts in primate stem cells</article-title><source>BMC Genomics</source><volume>18</volume><elocation-id>214</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-017-3568-y</pub-id><pub-id pub-id-type="pmid">28245871</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangel</surname><given-names>SC</given-names></name><name><surname>da Silva</surname><given-names>MD</given-names></name><name><surname>da Silva</surname><given-names>AL</given-names></name><name><surname>de MB Dos Santos</surname><given-names>J</given-names></name><name><surname>Neves</surname><given-names>LM</given-names></name><name><surname>Pedrosa</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>FM</given-names></name><name><surname>Trettel</surname><given-names>CDS</given-names></name><name><surname>Furtado</surname><given-names>GE</given-names></name><name><surname>de Barros</surname><given-names>MP</given-names></name><name><surname>Bachi</surname><given-names>ALL</given-names></name><name><surname>Romano</surname><given-names>CM</given-names></name><name><surname>Nali</surname><given-names>LHDS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Human endogenous retroviruses and the inflammatory response: A vicious circle associated with health and illness</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>1057791</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1057791</pub-id><pub-id pub-id-type="pmid">36518758</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebollo</surname><given-names>R</given-names></name><name><surname>Miceli-Royer</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Farivar</surname><given-names>S</given-names></name><name><surname>Gagnier</surname><given-names>L</given-names></name><name><surname>Mager</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Epigenetic interplay between mouse endogenous retroviruses and host genes</article-title><source>Genome Biology</source><volume>13</volume><elocation-id>R89</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2012-13-10-r89</pub-id><pub-id pub-id-type="pmid">23034137</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>J</given-names></name><name><surname>González</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia</article-title><source>Clinical and Experimental Rheumatology</source><volume>22</volume><fpage>554</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">15485007</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>LS</given-names></name><name><surname>da Silva Nali</surname><given-names>LH</given-names></name><name><surname>Leal</surname><given-names>COD</given-names></name><name><surname>Sabino</surname><given-names>EC</given-names></name><name><surname>Lacerda</surname><given-names>EM</given-names></name><name><surname>Kingdon</surname><given-names>CC</given-names></name><name><surname>Nacul</surname><given-names>L</given-names></name><name><surname>Romano</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HERV-K and HERV-W transcriptional activity in myalgic encephalomyelitis/chronic fatigue syndrome</article-title><source>Auto- Immunity Highlights</source><volume>10</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/s13317-019-0122-8</pub-id><pub-id pub-id-type="pmid">32257068</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Valle</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Potocki</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>S-HL</given-names></name><name><surname>Carlin</surname><given-names>ME</given-names></name><name><surname>Michel</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>P</given-names></name><name><surname>Cabrera-Meza</surname><given-names>G</given-names></name><name><surname>Brundage</surname><given-names>EK</given-names></name><name><surname>Eifert</surname><given-names>AL</given-names></name><name><surname>Stankiewicz</surname><given-names>P</given-names></name><name><surname>Cheung</surname><given-names>SW</given-names></name><name><surname>Lalani</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>HERV-mediated genomic rearrangement of EYA1 in an individual with branchio-oto-renal syndrome</article-title><source>American Journal of Medical Genetics. Part A</source><volume>152A</volume><fpage>2854</fpage><lpage>2860</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.33686</pub-id><pub-id pub-id-type="pmid">20979191</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>N</given-names></name><name><surname>Domingues</surname><given-names>P</given-names></name><name><surname>Golebiowski</surname><given-names>F</given-names></name><name><surname>Patzina</surname><given-names>C</given-names></name><name><surname>Tatham</surname><given-names>MH</given-names></name><name><surname>Hay</surname><given-names>RT</given-names></name><name><surname>Hale</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An influenza virus-triggered SUMO switch orchestrates co-opted endogenous retroviruses to stimulate host antiviral immunity</article-title><source>PNAS</source><volume>116</volume><fpage>17399</fpage><lpage>17408</lpage><pub-id pub-id-type="doi">10.1073/pnas.1907031116</pub-id><pub-id pub-id-type="pmid">31391303</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuvarikov</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>IM</given-names></name><name><surname>Dittwald</surname><given-names>P</given-names></name><name><surname>Neill</surname><given-names>NJ</given-names></name><name><surname>Bialer</surname><given-names>MG</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Wheeler</surname><given-names>PG</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Hannibal</surname><given-names>MC</given-names></name><name><surname>Murray</surname><given-names>MF</given-names></name><name><surname>Giovanni</surname><given-names>MA</given-names></name><name><surname>Terespolsky</surname><given-names>D</given-names></name><name><surname>Sodhi</surname><given-names>S</given-names></name><name><surname>Cassina</surname><given-names>M</given-names></name><name><surname>Viskochil</surname><given-names>D</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name><name><surname>Herman</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>CW</given-names></name><name><surname>Beck</surname><given-names>CR</given-names></name><name><surname>Gambin</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>SW</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Lamb</surname><given-names>AN</given-names></name><name><surname>Shaffer</surname><given-names>LG</given-names></name><name><surname>Ellison</surname><given-names>JW</given-names></name><name><surname>Ravnan</surname><given-names>JB</given-names></name><name><surname>Stankiewicz</surname><given-names>P</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Recurrent HERV-H-mediated 3q13.2-q13.31 deletions cause a syndrome of hypotonia and motor, language, and cognitive delays</article-title><source>Human Mutation</source><volume>34</volume><fpage>1415</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1002/humu.22384</pub-id><pub-id pub-id-type="pmid">23878096</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smets</surname><given-names>EM</given-names></name><name><surname>Garssen</surname><given-names>B</given-names></name><name><surname>Bonke</surname><given-names>B</given-names></name><name><surname>De Haes</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue</article-title><source>Journal of Psychosomatic Research</source><volume>39</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/0022-3999(94)00125-o</pub-id><pub-id pub-id-type="pmid">7636775</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>JB</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Relan</surname><given-names>P</given-names></name><name><surname>Diaz</surname><given-names>JV</given-names></name><collab>WHO Clinical Case Definition Working Group on Post-COVID-19 Condition</collab></person-group><year iso-8601-date="2022">2022</year><article-title>A clinical case definition of post-COVID-19 condition by A Delphi consensus</article-title><source>The Lancet. Infectious Diseases</source><volume>22</volume><fpage>e102</fpage><lpage>e107</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00703-9</pub-id><pub-id pub-id-type="pmid">34951953</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Perron</surname><given-names>H</given-names></name><name><surname>Feschotte</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Variation in proviral content among human genomes mediated by LTR recombination</article-title><source>Mobile DNA</source><volume>9</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1186/s13100-018-0142-3</pub-id><pub-id pub-id-type="pmid">30568734</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschopp</surname><given-names>R</given-names></name><name><surname>König</surname><given-names>RS</given-names></name><name><surname>Rejmer</surname><given-names>P</given-names></name><name><surname>Paris</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A preliminary survey among patients in Switzerland</article-title><source>Heliyon</source><volume>9</volume><elocation-id>e15595</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e15595</pub-id><pub-id pub-id-type="pmid">37131449</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Ba</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Downregulation of CD94/NKG2A inhibitory receptor on decreased γδ T cells in patients with systemic lupus erythematosus</article-title><source>Scandinavian Journal of Immunology</source><volume>76</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.2012.02705.x</pub-id><pub-id pub-id-type="pmid">22486170</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessely</surname><given-names>S</given-names></name><name><surname>Nimnuan</surname><given-names>C</given-names></name><name><surname>Sharpe</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Functional somatic syndromes: one or many?</article-title><source>The Lancet</source><volume>354</volume><fpage>936</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)08320-2</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Ggplot2, Elegant Graphics for Data Analysis. R</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-24277-4</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Smythe</surname><given-names>HA</given-names></name><name><surname>Yunus</surname><given-names>MB</given-names></name><name><surname>Bennett</surname><given-names>RM</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Goldenberg</surname><given-names>DL</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name><name><surname>Campbell</surname><given-names>SM</given-names></name><name><surname>Abeles</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>P</given-names></name><name><surname>Fam</surname><given-names>AG</given-names></name><name><surname>Farber</surname><given-names>SJ</given-names></name><name><surname>Fiechtner</surname><given-names>JJ</given-names></name><name><surname>Michael Franklin</surname><given-names>C</given-names></name><name><surname>Gatter</surname><given-names>RA</given-names></name><name><surname>Hamaty</surname><given-names>D</given-names></name><name><surname>Lessard</surname><given-names>J</given-names></name><name><surname>Lichtbroun</surname><given-names>AS</given-names></name><name><surname>Masi</surname><given-names>AT</given-names></name><name><surname>Mccain</surname><given-names>GA</given-names></name><name><surname>John Reynolds</surname><given-names>W</given-names></name><name><surname>Romano</surname><given-names>TJ</given-names></name><name><surname>Jon Russell</surname><given-names>I</given-names></name><name><surname>Sheon</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The american college of rheumatology 1990 criteria for the classification of fibromyalgia</article-title><source>Arthritis &amp; Rheumatism</source><volume>33</volume><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1002/art.1780330203</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Clauw</surname><given-names>DJ</given-names></name><name><surname>Fitzcharles</surname><given-names>M</given-names></name><name><surname>Goldenberg</surname><given-names>DL</given-names></name><name><surname>Katz</surname><given-names>RS</given-names></name><name><surname>Mease</surname><given-names>P</given-names></name><name><surname>Russell</surname><given-names>AS</given-names></name><name><surname>Russell</surname><given-names>IJ</given-names></name><name><surname>Winfield</surname><given-names>JB</given-names></name><name><surname>Yunus</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity</article-title><source>Arthritis Care &amp; Research</source><volume>62</volume><fpage>600</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1002/acr.20140</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Clauw</surname><given-names>DJ</given-names></name><name><surname>Fitzcharles</surname><given-names>MA</given-names></name><name><surname>Goldenberg</surname><given-names>DL</given-names></name><name><surname>Häuser</surname><given-names>W</given-names></name><name><surname>Katz</surname><given-names>RL</given-names></name><name><surname>Mease</surname><given-names>PJ</given-names></name><name><surname>Russell</surname><given-names>AS</given-names></name><name><surname>Russell</surname><given-names>IJ</given-names></name><name><surname>Walitt</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Revisions to the 2010/2011 fibromyalgia diagnostic criteria</article-title><source>Seminars in Arthritis and Rheumatism</source><volume>46</volume><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2016.08.012</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innovation</source><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human endogenous retrovirus HERV-H family in human tissues and cancer cells: expression, identification, and phylogeny</article-title><source>Cancer Letters</source><volume>231</volume><fpage>228</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.02.001</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Preissl</surname><given-names>S</given-names></name><name><surname>Amaral</surname><given-names>ML</given-names></name><name><surname>Grinstein</surname><given-names>JD</given-names></name><name><surname>Farah</surname><given-names>EN</given-names></name><name><surname>Destici</surname><given-names>E</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>Chee</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Izpisua Belmonte</surname><given-names>JC</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name><name><surname>Chi</surname><given-names>NC</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptionally active HERV-H retrotransposons demarcate topologically associating domains in human pluripotent stem cells</article-title><source>Nature Genetics</source><volume>51</volume><fpage>1380</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0479-7</pub-id><pub-id pub-id-type="pmid">31427791</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Chinai</surname><given-names>JM</given-names></name><name><surname>Buhl</surname><given-names>S</given-names></name><name><surname>Scandiuzzi</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name><name><surname>Jeon</surname><given-names>H</given-names></name><name><surname>Ohaegbulam</surname><given-names>KC</given-names></name><name><surname>Ghosh</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>A</given-names></name><name><surname>Scharff</surname><given-names>MD</given-names></name><name><surname>Zang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function</article-title><source>PNAS</source><volume>110</volume><fpage>9879</fpage><lpage>9884</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303524110</pub-id><pub-id pub-id-type="pmid">23716685</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>CH</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Protective role of γδ T cells in different pathogen infections and its potential clinical application</article-title><source>Journal of Immunology Research</source><volume>2018</volume><elocation-id>5081634</elocation-id><pub-id pub-id-type="doi">10.1155/2018/5081634</pub-id><pub-id pub-id-type="pmid">30116753</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104441.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dopkins</surname><given-names>Nicholas</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Northwell Health</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study substantially expands observations of HERV expression in the clinical settings. The evidence provided by the authors that HERV activity is an underlying etiological factor in ME/CFS and fibromyalgia is <bold>compelling</bold> and suggests further investigation into mechanisms. This work will be of broad interest to clinicians and researchers alike.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104441.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Giménez-Orenga et al. investigate the origin and pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM). Using RNA microarrays, the authors compare the expression profiles and evaluate the biomarker potential of human endogenous retroviruses (HERV) in these two conditions. Altogether, the authors show that HERV expression is distinct between ME/CFS and FM patients, and HERV dysregulation is associated with higher symptom intensity in ME/CFS. HERV expression in ME/CFS patients is associated with impaired immune function and higher estimated levels of plasma cells and resting CD4 memory T cells. This work provides interesting insights into the pathophysiology of ME/CFS and FM, creating opportunities for several follow-up studies.</p><p>Strengths:</p><p>(1) Overall, the data is convincing and supports the authors' claims. The manuscript is clear and easy to understand, and the methods are generally well-detailed. It was quite enjoyable to read.</p><p>(2) The authors combined several unbiased approaches to analyse HERV expression in ME/CFS and FM. The tools, thresholds, and statistical models used all seem appropriate to answer their biological questions.</p><p>(3) The authors propose an interesting alternative to diagnosing these two conditions. Transcriptomic analysis of blood samples using an RNA microarray could allow a minimally invasive and reproducible way of diagnosing ME/CFS and FM.</p><p>Weakness:</p><p>(1) While this work makes several intriguing observations, some results will need to be validated in future studies using experimental approaches.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104441.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Giménez-Orenga carried out this study to assess whether human endogenous retroviruses (HERVs) could be used to improve the diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia (FM). To this end, they used the HERV-V3 array developed previously, to characterize the genome-wide changes in expression of HERVs in patients suffering from ME/CFS, FM or both, compared to controls. In turn, they present a useful repertoire of HERVs that might characterize ME/CFS and FM. For most part, the paper is written in a manner that allows a natural understanding of the workflow and analyses carried out, making it compelling. The figures and additional tables presents solid support for the findings. However, some statements made by the authors seem incomplete and would benefit by a more thorough literature review. Overall, this work will be of interest to the medical community seeking in better understanding the co-occurrence of these pathologies, hinting at a novel angle by integrating HERVs, which are often overlooked, into their assessment.</p><p>Strengths:</p><p>- The work is well-presented, allowing the reader to understand the overall workflow and how the specific aims contribute to filling the knowledge gap in the field.</p><p>- The analyses carried out to understand the potential impact on gene expression mediated by HERVs are in line with previous works, making it solid and robust in the context of this study.</p><p>Weaknesses:</p><p>- The authors claim to obtain genome-wide HERV expression profiles. However, the array used was developed using hg19, while the genomic analysis of this work are carried out using a liftover to hg38. It would improve the statement and findings to include a comparation of the differences in HERVs available in hg38, and how this could impact the &quot;genome-wide&quot; findings.</p><p>- The authors in some points are not thorough with the cited literature. Two examples are:</p><p>(1) Lines 396-397 the authors say &quot;the MLT1, usually found enriched near DE genes (Bogdan et al., 2020)&quot;. I checked the work by Bogdan, and they studied bacterial infection. A single work in a specific topic is not sufficient to support the statement that MLT1 is &quot;usually&quot; in close vicinity to differentially expressed genes. More works are needed to support this.</p><p>(2) After the previous statement, the authors go on to mention &quot;contributing to the coding of conserved lncRNAs (Ramsay et al., 2017)&quot;. First, lnc = long non-coding, so this doesn't make sense. Second, in the work by Ramsay they mention &quot;that contributed a significant amount of sequence to primate lncRNAs whose expression was conserved&quot;, which is different to what the authors in this study are trying to convey. Again, additional work and a rephrasing might help to support this idea.</p><p>- When presenting the clusters, the authors overlook the fact that cluster 4 is clearly control-specific, and fail to discuss what this means. Could this subset of HERV be used as bona fide markers of healthy individuals in the context of these diseases? Are they associated with DE genes? What could be the impact of such associations?</p><p>Appraisals on aims:</p><p>The authors set specific questions and presented the results to successfully answer them. The evidence is solid, with some weaknesses discussed above that will methodologically strengthen the work.</p><p>Likely impact of work on the field:</p><p>This work will be of interest to the medical community looking for novel ways to improve clinical diagnosis. Although future works with a greater population size, and more robust techniques such as RNA-Seq, are needed, this is the first step in presenting a novel way to distinguish these pathologies.</p><p>It would be of great benefit to the community to provide a table/spreadsheet indicating the specific genomic locations of the HERVs specific to each condition. This will allow proper provenance for future researchers interesting in expanding on this knowledge, as these genomic coordinates will be independent of the technique used (as was the array used here).</p><p>Comments on revisions:</p><p>When addressing the comments made in the previous round, there are some answers that lack substance and don't seem to be incorporated in the manuscript. For example, the authors say:</p><p>Authors' response: This is an important point. However, the low number of probes (less than 100) that were excluded from our analysis by lack of correspondence with hg38 among the 1,290,800 probesets was interpreted as insignificant for &quot;genome-wide&quot; claims. An aspect that will be explained in the revised version of this manuscript.</p><p>I checked the revised manuscript with tracked changes, and there doesn't seem to be an updated explanation to this. In which lines is this explained?</p><p>For the other response:</p><p>Authors' response: Using control DE HERV as bona fide markers of healthy individuals seems like an interesting possibility worth exploring. Control DE HERV (cluster 4) associate with DE genes involved in apoptosis, T cell activation and cell-cell adhesion (modules 1 and 6). The impact of which deserves further study.</p><p>I couldn't find an updated mention of this in the discussion.</p><p>Another point that I raised was regarding the decision of using an FDR of 0.1 instead of 0.05. The authors only speculate about the impacts in their answer, while I believe that this could have been rigorously addressed. Since this was done in R, and DE analysis are relatively fast, I don't see a reason as to why this part was not repeated and discussed accordingly.</p><p>For other analyses, there doesn't seem to be a problem with using 0.05 as threshold. Examples of this are the &quot;Overrepresentation functional analysis&quot;, or the &quot;Statistical analysis&quot; part of the methods they say &quot;we used a Fisher exact test to calculate p-value, considering enriched in the provided list if an adjusted p-value (FDR) was less than 0.05&quot;.</p><p>Just to make this point clear: I'm not asking the authors to repeat all the work using the 0.05 FDR threshold, but rather that they are aware and conscious about the impact of this, and give an idea to the audience on how it would change the DE numbers. This would put in perspective the findings to any future reader.</p><p>I think that most of the other answers to both my previous concerns and the other reviewer's concerns are ok. My last outstanding concern is that the probe coordinates apparently can't be shared, which undermines a lot this study reproducibility, and its use by future researches which won't be able to compare their results to this study.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104441.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors find that HERV expression patterns can be used as new criteria for differential diagnosis of FM and ME/CFS and patient subtyping. The data are based on transcriptome analysis by microarray for HERVs using patient blood samples, followed by differential expression of ERVs and bioinformatic analyses. This is a standard and solid data processing pipeline, and the results are well presented and support the authors' claim.</p><p>Strengths:</p><p>It provides an innovative diagnostic approach using ERV profiles to subtype patients and distinguish FM and ME/CFS.</p><p>Comments on revisions:</p><p>This is a revised manuscript which addresses the comments well.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.104441.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Giménez-Orenga</surname><given-names>Karen</given-names></name><role specific-use="author">Author</role><aff><institution>Escuela de Doctorado, Catholic University of Valencia</institution><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Martín-Martínez</surname><given-names>Eva</given-names></name><role specific-use="author">Author</role><aff><institution>Manises Hospital</institution><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff></contrib><contrib contrib-type="author"><name><surname>Nathanson</surname><given-names>Lubov</given-names></name><role specific-use="author">Author</role><aff><institution>Nova Southeastern University</institution><addr-line><named-content content-type="city">Ft Lauderdale</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Oltra</surname><given-names>Elisa</given-names></name><role specific-use="author">Author</role><aff><institution>Catholic University of Valencia</institution><addr-line><named-content content-type="city">Valencia</named-content></addr-line><country>Spain</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>Giménez-Orenga et al. investigate the origin and pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM). Using RNA microarrays, the authors compare the expression profiles and evaluate the biomarker potential of human endogenous retroviruses (HERV) in these two conditions. Altogether, the authors show that HERV expression is distinct between ME/CFS and FM patients, and HERV dysregulation is associated with higher symptom intensity in ME/CFS. HERV expression in ME/CFS patients is associated with impaired immune function and higher estimated levels of plasma cells and resting CD4 memory T cells. This work provides interesting insights into the pathophysiology of ME/CFS and FM, creating opportunities for several follow-up studies.</p><p>Strengths:</p><p>(1) Overall, the data is convincing and supports the authors' claims. The manuscript is clear and easy to understand, and the methods are generally well-detailed. It was quite enjoyable to read.</p><p>(2) The authors combined several unbiased approaches to analyse HERV expression in ME/CFS and FM. The tools, thresholds, and statistical models used all seem appropriate to answer their biological questions.</p><p>(3) The authors propose an interesting alternative to diagnosing these two conditions. Transcriptomic analysis of blood samples using an RNA microarray could allow a minimally invasive and reproducible way of diagnosing ME/CFS and FM.</p><p>Weaknesses:</p><p>(1) The cohort analysed in this study was phenotyped by a single clinician. As ME/CFS and FM are diagnosed based on unspecific symptoms and are frequently misdiagnosed, this raises the question of whether the results can be generalised to external cohorts.</p></disp-quote><p>Thank you for your comment. Surely the study of larger cohorts will determine the external validity of these results in a clinical scenario. However, this pilot study, first of its kind, was designed to maximize homogeneity across participants which seemed primarily ensured by the study of females only and diagnosis by a single experienced observer.</p><disp-quote content-type="editor-comment"><p>(2) The analyses performed to unravel the causes and effects of HERV expression in ME/CFS and FM are solely based on sequencing data. Experimental approaches could be used to validate some of the transcriptomic observations.</p></disp-quote><p>Certainly, experimental approaches may add robustness to the implication of HERVs in ME/CFS. We indeed consider taking this avenue to deepen in the findings presented here for future work. However, the limited knowledge of HERV-mediated physiological functions may hamper the obtention of prompt results towards revealing causes and effects of HERV expression in ME/CFS and FM.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>Giménez-Orenga carried out this study to assess whether human endogenous retroviruses (HERVs) could be used to improve the diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia (FM). To this end, they used the HERV-V3 array developed previously, to characterize the genome-wide changes in the expression of HERVs in patients suffering from ME/CFS, FM, or both, compared to controls. In turn, they present a useful repertoire of HERVs that might characterize ME/CFS and FM. For the most part, the paper is written in a manner that allows a natural understanding of the workflow and analyses carried out, making it compelling. The figures and additional tables present solid support for the findings. However, some statements made by the authors seem incomplete and would benefit from a more thorough literature review. Overall, this work will be of interest to the medical community seeking in better understanding of the co-occurrence of these pathologies, hinting at a novel angle by integrating HERVs, which are often overlooked, into their assessment.</p><p>Strengths:</p><p>(1) The work is well-presented, allowing the reader to understand the overall workflow and how the specific aims contribute to filling the knowledge gap in the field.</p><p>(2) The analyses carried out to understand the potential impact on gene expression mediated by HERVs are in line with previous works, making it solid and robust in the context of this study.</p><p>Weaknesses:</p><p>(1) The authors claim to obtain genome-wide HERV expression profiles. However, the array used was developed using hg19, while the genomic analysis of this work are carried out using a liftover to hg38. It would improve the statement and findings to include a comparison of the differences in HERVs available in hg38, and how this could impact the &quot;genome-wide&quot; findings.</p></disp-quote><p>This is an important point. However, the low number of probes (less than 100) that were excluded from our analysis by lack of correspondence with hg38 among the 1,290,800 probesets was interpreted as insignificant for &quot;genome-wide&quot; claims. An aspect that will be explained in the revised version of this manuscript.</p><disp-quote content-type="editor-comment"><p>(2) The authors in some points are not thorough with the cited literature. Two examples are:</p><p>a) Lines 396-397 the authors say &quot;the MLT1, usually found enriched near DE genes (Bogdan et al., 2020)&quot;. I checked the work by Bogdan, and they studied bacterial infection. A single work in a specific topic is not sufficient to support the statement that MLT1 is &quot;usually&quot; in close vicinity to differentially expressed genes. More works are needed to support this.</p><p>b) After the previous statement, the authors go on to mention &quot;contributing to the coding of conserved lncRNAs (Ramsay et al., 2017)&quot;. First, lnc = long non-coding, so this doesn't make sense. Second, in the work by Ramsay they mention &quot;that contributed a significant amount of sequence to primate lncRNAs whose expression was conserved&quot;, which is different from what the authors in this study are trying to convey. Again, additional work and a rephrasing might help to support this idea.</p></disp-quote><p>Certainly, these two sentences need rephrasing to better adjust to current evidence.</p><p>Revised sentences can now be found in lines 397-402</p><disp-quote content-type="editor-comment"><p>(3) When presenting the clusters, the authors overlook the fact that cluster 4 is clearly control-specific, and fail to discuss what this means. Could this subset of HERV be used as bona fide markers of healthy individuals in the context of these diseases? Are they associated with DE genes? What could be the impact of such associations?</p></disp-quote><p>Using control DE HERV as bona fide markers of healthy individuals seems like an interesting possibility worth exploring. Control DE HERV (cluster 4) associate with DE genes involved in apoptosis, T cell activation and cell-cell adhesion (modules 1 and 6). The impact of which deserves further study.</p><disp-quote content-type="editor-comment"><p>Appraisals on aims:</p><p>The authors set specific questions and presented the results to successfully answer them. The evidence is solid, with some weaknesses discussed above that will methodologically strengthen the work.</p><p>Likely impact of work on the field:</p><p>This work will be of interest to the medical community looking for novel ways to improve clinical diagnosis. Although future works with a greater population size, and more robust techniques such as RNA-Seq, are needed, this is the first step in presenting a novel way to distinguish these pathologies.</p><p>It would be of great benefit to the community to provide a table/spreadsheet indicating the specific genomic locations of the HERVs specific to each condition. This will allow proper provenance for future researchers interested in expanding on this knowledge, as these genomic coordinates will be independent of the technique used (as was the array used here).</p></disp-quote><p>We agree with the reviewer that sharing genomic locations of DE HERVs in these pathologies would contribute to the development of these findings. Unfortunately, we do not hold the rights to share probe coordinates from this custom HERV-V3 microarray which we used under MTA agreement with its developer.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>The authors find that HERV expression patterns can be used as new criteria for differential diagnosis of FM and ME/CFS and patient subtyping. The data are based on transcriptome analysis by microarray for HERVs using patient blood samples, followed by differential expression of ERVs and bioinformatic analyses. This is a standard and solid data processing pipeline, and the results are well presented and support the authors' claim.</p><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>Recommandations/questions:</p><p>(1) The authors point towards the biomarker potential of HERV expression signatures. In line with this, it would be important to test if they can predict the correct pathology for patients using the expression of DE HERVs. Additionally, as a single clinician annotated the cohort analysed in this study, it would be interesting to validate the signatures identified in this work by reanalysing publicly available transcriptomic data from independent studies.</p></disp-quote><p>Thank you for the suggestion. We plan to conduct this analysis and have added the following statement to the manuscript (lines 482-483): “Given the limited sample size in our cohort, validation of the findings in extended cohorts is a must.”</p><disp-quote content-type="editor-comment"><p>(2) The authors suggest that an epigenetic mechanism causes the dysregulated HERV expression in ME/CFS patients. However, in Fig.1A, HERV expression profiles of co-diagnosed patients are more similar to healthy controls than patients with either condition. How could the co-morbidity of FM &quot;rescue&quot; the phenotype of ME/CFS?</p></disp-quote><p>Thank you for the insightful comment. It is notable that co-diagnosed patients exhibit HERV expression profiles more similar to those of healthy controls than to either FM´s or ME/CFS´s. These findings may suggest a distinct underlying pathomechanism for this patient group, supporting the identification of a novel nosologic entity, as discussed in lines 372-374 of the manuscript.</p><disp-quote content-type="editor-comment"><p>(3) Abundant evidence in the literature links HERV dysregulation with the production of RNA:DNA hybrids and dsRNAs and viral mimicry. The authors found that ME/CFS subgroup 2, which exhibits the most important HERV dysregulation, is also associated with decreased signatures of pathogen detection. It would be interesting to quantify the abundance of DNA:RNA hybrids and dsRNAs in PBMCs of ME/CFS and FM patients as well as healthy controls. It would be interesting to discuss how downregulation of pathogen detection pathways could be a mechanism in ME/CFS patients to avoid viral mimicry and potential links with inflammation in this disease.</p></disp-quote><p>Certainly, HERVs can influence disease pathophysiology by generating RNA:DNA hybrids and dsRNA. However, microarray data does not allow this analysis. Future actions to investigate the underlying mechanisms of differentially expressed HERVs could investigate this interesting possibility.</p><disp-quote content-type="editor-comment"><p>(4) Another intriguing result is how overexpression of Module 3 in ME/CFS subgroup 2 is associated with higher levels of plasma cells. The authors hypothesize that the changes in immune cell abundances reflect previous viral infections, but another possibility would be immune activation against HERVs. Are there protein-coding sequences (gag, pro, pol, env) amongst the HERV sequences of module 3? If so, it would be interesting to validate HERV protein expression in these samples. Additionally, blood samples of ME/CFS patients and healthy controls should be analysed in flow cytometry to describe the abundance and phenotype of immune cells precisely.</p></disp-quote><p>Thank you for your insightful comments. In fact, we identified three HERV elements with protein-coding regions whose functional relevance remains uncertain. They present an interesting avenue for future investigation, particularly regarding immune activation.</p><disp-quote content-type="editor-comment"><p>Minor comments:</p><p>(1) On lines 170-172, it is unclear to me how Figure 1E is linked to the text.</p></disp-quote><p>We have added a line better explaining Fig. 1E: “Top 10 contributing HERVs to principal components PC1 and PC2 are shown” (lines 171-172).</p><disp-quote content-type="editor-comment"><p>(2) Figure S2: grouping or colouring the plots based on the cluster to which HERVs were assigned could facilitate the understanding of the figure.</p></disp-quote><p>We appreciate the suggestion to enhance the clarity of the figures. However, this color-coding cannot be implemented, as a family is not exclusively assigned to a single cluster.</p><disp-quote content-type="editor-comment"><p>(3) How are the 4 HERV clusters of Figure 2 and the 8 modules of Figure 3 related to the clusters identified by hierarchical clustering in Figure 1? More details should be provided in the text (Results and Methods sections), and figures to illustrate the clustering strategy should be added if needed.</p></disp-quote><p>To enhance clarity, we have included the following explanation in the results section (lines 244-251): “To uncover potentially affected physiologic functions linked to DE HERV, we examined how DE HERVs and DE genes with similar expression patterns grouped together in modules based on their intrinsic relationships by their hierarchical co-clustering (Fig. 3). Then, the functional significance of these modules was assessed by gene ontology (GO) analysis of the DE genes within each module. The hierarchical clustering analysis resulted in the identification of eight distinct modules, each characterized by unique combinations of DE HERV and DE gene patterns across all four study groups (Fig. 3)”.</p><disp-quote content-type="editor-comment"><p>(4) Related to Figure 4, are there HERV sequences in module 3 located near genes important for plasma cells and/or resting CD4 memory T cells?</p></disp-quote><p>Thank you for your insightful comment. However, gene relevance for plasma cells and/or resting CD4 memory T cells may depend on multiple factors in addition to cell type and subtypes and, therefore, the analysis may not be straight forward.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>In Figure 1, the heatmap scale goes from -4 to 4. This should reflect at least the numbers on the lowest and highest end of the scale.</p></disp-quote><p>Thank you for bringing this to our attention. The scale was correct; however, when arranging the panels, the numbers were not properly positioned. The figure has now been updated with the corrected version.</p><disp-quote content-type="editor-comment"><p>Figure 2F and G, percentages are shown as decimal numbers up to 1.00, while it should be 100%, and so on.</p></disp-quote><p>We also replaced this figure, changing the numbers to fit percentages.</p><disp-quote content-type="editor-comment"><p>It would be interesting to know how the results change using FDR of 0.05. I'm not familiar with microarray thresholds, but in RNA-Seq, 0.1 is rarely used, with 0.05 being the standard. Could it be that a more stringent result better distinguishes the pathologies?</p></disp-quote><p>Applying a more stringent threshold, such as FDR 0.05, may remove sequences that, while not strongly differentially expressed, may be still important for distinguishing between these pathologies. Therefore, we decided to also include DE tendencies (FDR&lt;0.1) in this first of a kind study. Findings will need validation in enlarged cohorts.</p></body></sub-article></article>